Salts of Pim kinase inhibitors
Patent Information
- Application Number
- CN201680057727.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2016-09-09
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
[0322] Tablets or pills of the present invention may be coated or otherwise compounded to provide dosage forms that provide the advantage of prolonged action. For example, a tablet or pill may contain an inner dosage and an outer dosage component, the latter in the form of a coating surrounding the former. The two components may be separated by an enteric coating layer that resists disintegration in the stomach and allows the inner component to pass intact into the duodenum or to delay release. A variety of materials may be used for the enteric layer or coating, including large amounts of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.
Smart Images

Figure CN108349938B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a salt form of a Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including a preparation method thereof and intermediates for preparing the same, wherein the compound can be used to treat Pim kinase-related diseases, such as cancer. Background of the Invention
[0003] Overexpression of Pim kinases has been detected in a wide variety of hematological and solid cancers. Overexpression of multiple family members has been noted in multiple myeloma, AML, pancreatic cancer, and hepatocellular carcinoma. Claudio et al., Blood 2002, 100, 2175-86; Amson et al., Proc. Nat. Acad. Sci. USA, 1989, 86, 8857-61; Mizuki et al., Blood, 2003, 101, 3164-73; Li et al., Canc. Res., 2006, 66, 6741-7; Fujii et al., Int. J. Canc., 2005, 114, 209-18. Overexpression of Pim1 causes poor prognosis in mantle cell lymphoma, esophageal cancer, and head and neck cancer. Hsi et al., Leuk. Lymph., 2008, 49, 2081-90; Liu et al., J. Surg. Oncol., 2010, 102, 683-88; Peltola et al., Neoplasia, 2009, 11, 629-36. Pim2 overexpression causes an aggressive clinical course in a subset of DLBCL patients. Gomez-Abad et al., Blood, 2011, 118, 5517-27. Overexpression of Myc is often seen and Pim kinases can convey resistance to traditional chemotherapeutic agents and radiation. Chen et al., Blood, 2009, 114, 4150-57; Isaac et al., Drug Resis. Updates, 2011, 14, 203-11; Hsu et al., Cancer Lett., 2012, 319, 214; Peltola et al., Neoplasia, 2009, 11, 629-36. Thus, these data suggest that inhibition of Pim kinases would be useful in providing therapeutic benefit to cancer patients.
[0004] Pim kinase inhibitors have been described, for example, in U.S. Patent Publication Nos. 2014 / 0200216, 2014 / 0200227, and 2015 / 0057265. Specifically, U.S. Patent Publication No. 2014 / 0200227 describes the Pim inhibitory compound N-{4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (including both 7R and 7S diastereomers). Therefore, new forms of Pim inhibitory molecules are needed to facilitate the preparation of pharmaceutically suitable formulations and dosage forms having suitable properties that can, for example, facilitate the manufacture of safe, effective, high-quality pharmaceutical products. The invention described herein is directed to this goal. SUMMARY OF THE INVENTION
[0005] The present invention is directed to salts of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide.
[0006] The present invention is further directed to the phosphate salt of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide.
[0007] The present invention is further directed to a crystalline form of the phosphate salt of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide.
[0008] The present invention is further directed to the dihydrochloride salt of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide.
[0009] The present invention is further directed to the monohydrochloride salt of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide.
[0010] The present invention further relates to the maleate, adipate, hydrobromide, (R)-(-)-mandelate, salicylate, benzoate, pyroglutamate, methanesulfonate, (1S)-(+)-10-camphorsulfonate, fumarate, sulfate, L-tartrate and D-tartrate salts of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide.
[0011] The present invention is further directed to crystalline forms of the salts described herein.
[0012] The present invention is further directed to a pharmaceutical composition comprising a salt or crystalline form as described herein and at least one pharmaceutically acceptable carrier.
[0013] The present invention is further directed to methods of treatment using the salts and crystalline forms described herein.
[0014] The present invention is further directed to methods of preparing the salts and crystalline forms described herein.
[0015] The invention is further directed to intermediates useful in preparing the salts and crystalline forms described herein.
[0016] Simple illustration
[0017] Figure 1 The XRPD pattern of Compound 1 phosphate salt Form I is shown.
[0018] Figure 2 Shown is the DSC thermogram of Compound 1 phosphate salt Form I.
[0019] Figure 3 Shown is a TGA thermogram of Compound 1 phosphate salt Form I.
[0020] Figure 4 Shown is the XRPD pattern of the solid form of Compound 1 dihydrochloride salt.
[0021] Figure 5 Shown is a DSC thermogram of a solid form of Compound 1 dihydrochloride.
[0022] Figure 6Shown is a TGA thermogram of the solid form of Compound 1 dihydrochloride.
[0023] Figure 7 The XRPD pattern of Compound 1 phosphate salt Form II is shown.
[0024] Figure 8 Shown is the DSC thermogram of Compound 1 phosphate salt Form II.
[0025] Fig. 9 Shown is a TGA thermogram of Compound 1 phosphate salt Form II.
[0026] Fig.10 The XRPD pattern of Compound 1 phosphate salt Form III is shown.
[0027] Fig.11 Shown is the DSC thermogram of Compound 1 phosphate salt Form III.
[0028] Fig.12 Shown is a TGA thermogram of Compound 1 phosphate salt Form III.
[0029] Fig.13 The XRPD pattern of Compound 1 phosphate salt Form IV is shown.
[0030] Fig.14 Shown is the DSC thermogram of Compound 1 phosphate salt Form IV.
[0031] Fig.15 Shown is a TGA thermogram of Compound 1 phosphate salt Form IV.
[0032] Fig.16 The XRPD pattern of Compound 1 phosphate salt Form V is shown.
[0033] Fig.17 Shown is the DSC thermogram of Compound 1 phosphate salt Form V.
[0034] Fig.18 Shown is a TGA thermogram of Compound 1 phosphate salt Form V.
[0035] Fig.19 The XRPD pattern of Compound 1 phosphate salt Form VI is shown.
[0036] Fig. 20 Shown is the DSC thermogram of Compound 1 phosphate salt Form VI.
[0037] Fig.21 Shown is the TGA thermogram of Compound 1 phosphate salt Form VI.
[0038] Fig. 22 Shown is the XRPD pattern of the solid form of Compound 1 monohydrochloride salt.
[0039] Fig.23 Shown is the DSC thermogram of the solid form of Compound 1 monohydrochloride.
[0040] Fig.24 Shown is the XRPD pattern of the solid form of Compound 1 maleate salt.
[0041] Fig.25 Shown is a DSC thermogram of the solid form of Compound 1 maleate salt.
[0042] Fig.26 Shown is a TGA thermogram of the solid form of Compound 1 maleate salt.
[0043] Fig. 27 Shown is the XRPD pattern of the solid form of Compound 1 adipate salt.
[0044] Fig.28 Shown is a DSC thermogram of the solid form of Compound 1 adipate salt.
[0045] Fig.29 Shown is a TGA thermogram of the solid form of Compound 1 adipate salt.
[0046] Fig.30 Shown is the XRPD pattern of the solid form of Compound 1 hydrobromide salt.
[0047] Fig.31 Shown is a DSC thermogram of the solid form of Compound 1 hydrobromide salt.
[0048] Fig.32 Shown is a TGA thermogram of the solid form of Compound 1 hydrobromide salt.
[0049] Fig.33 Shown is the XRPD pattern of the solid form of Compound 1 R-(-)-mandelate salt.
[0050] Fig.34 Shown is the DSC thermogram of the solid form of Compound 1 R-(-)-mandelate salt.
[0051] Fig.35 Shown is a TGA thermogram of the solid form of Compound 1 R-(-)-mandelate salt.
[0052] Fig.36 Shown is the XRPD pattern of the solid form of Compound 1 salicylate salt.
[0053] Fig.37 Shown is the DSC thermogram of the solid form of Compound 1 salicylate salt.
[0054] Fig.38Shown is the XRPD pattern of the solid form of Compound 1 benzoate salt.
[0055] Fig.39 Shown is the XRPD pattern of the solid form of Compound 1 besylate salt.
[0056] Fig.40 Shown is the XRPD pattern of the solid form of Compound 1 L-pyroglutamate salt.
[0057] Fig.41 Shown is the XRPD pattern of the solid form of Compound 1 mesylate salt.
[0058] Fig.42 Shown is the XRPD pattern of the solid form of Compound 1 (1S)-(+)-10-camsylate salt.
[0059] Fig.43 Shown is the XRPD pattern of the solid form of Compound 1 fumarate salt.
[0060] Fig.44 Shown is the XRPD pattern of the solid form of Compound 1 sulfate salt.
[0061] Fig.45 Shown is the XRPD pattern of the solid form of Compound 1 L-tartrate salt.
[0062] Fig.46 Shown is the XRPD pattern of the solid form of Compound 1 D-tartrate salt. DETAILED DESCRIPTION OF THE INVENTION
[0064] The present invention is particularly directed to salts of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1), the structure of which is shown below.
[0065]
[0066] Compound 1 and its salt are Pim kinase inhibitors and can be used to treat diseases in which, for example, one or more Pim kinases (e.g., Pim1, Pim2 and / or Pim3) are upregulated. In some embodiments, the salt of Compound 1 provided herein is in solid form. In some embodiments, the present invention relates to a solid form comprising a salt provided herein. In some embodiments, the solid form is crystalline.
[0067] In some embodiments, the salt of the invention is a phosphate salt of Compound 1, such as a monophosphate salt form. The monophosphate form of Compound 1 is referred to herein as "Compound 1 phosphoric acid salt," "Compound 1 phosphate," or "Compound 1 phosphate." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide phosphate.
[0068] In some embodiments, the salt of the invention is a hydrochloride salt of Compound 1, such as a dihydrochloride salt. The dihydrochloride salt form of Compound 1 is referred to herein as "Compound 1 dihydrochloric acidsalt," "Compound 1 dihydrochloric acid," or "Compound 1 dihydrochloride." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide dihydrochloride.
[0069] In some embodiments, the hydrochloride salt of Compound 1 is the monohydrochloride salt of Compound 1. The monohydrochloride salt form of Compound 1 is referred to herein as "Compound 1 monohydrochloric acid salt," "Compound 1 monohydrochloric acid," or "Compound 1 monohydrochloride." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide monohydrochloride.
[0070] In some embodiments, the salt of the invention is the maleic acid (cis-butenedioic acid) salt of Compound 1. The maleic acid salt form of Compound 1 is referred to herein as "Compound 1 maleic acid salt," "Compound 1 maleic acid," or "Compound 1 maleate." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide maleate.
[0071] In some embodiments, the salt of the invention is an adipate salt of Compound 1. The adipate salt form of Compound 1 is referred to herein as "Compound 1 adipic acid salt," "Compound 1 adipic acid," or "Compound 1 adipate." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide adipate.
[0072] In some embodiments, the salt of the present invention is a hydrobromide salt of Compound 1. In some embodiments, the hydrobromide salt of Compound 1 is in the form of a dihydrobromide salt. In some embodiments, the hydrobromide salt of Compound 1 is in the form of a monohydrobromide salt. The hydrobromide salt form of Compound 1 is referred to herein as "Compound 1 hydrobromicacid salt," "Compound 1 hydrobromic acid," or "Compound 1 hydrobromide." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide hydrobromide.
[0073] In some embodiments, the salt of the invention is a (R)-(-)-mandelate salt of Compound 1. In some embodiments, the (R)-(-)-mandelate salt of Compound 1 is a mono-(R)-(-)-mandelate salt. In some embodiments, the (R)-(-)-mandelate salt of Compound 1 is a di-(R)-(-)-mandelate salt. The (R)-(-)-mandelate salt form of Compound 1 is referred to herein as "Compound 1 mandelic acid salt," "Compound 1 mandelic acid," or "Compound 1 mandelate." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide mandelate.
[0074] In some embodiments, the salt of the present invention is a salicylate salt of Compound 1. In some embodiments, the salicylate salt of Compound 1 is a monosalicylate salt. In some embodiments, the salicylate salt of Compound 1 is a disalicylate salt. The salicylate salt form of Compound 1 is referred to herein as "Compound 1 salicylic acid salt", "Compound 1 salicylic acid" or "Compound 1 salicylate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide salicylate.
[0075] In some embodiments, the salt of the present invention is a benzoate salt of Compound 1. In some embodiments, the benzoate salt of Compound 1 is a monobenzoate salt. In some embodiments, the benzoate salt of Compound 1 is a dibenzoate salt. The benzoate salt form of Compound 1 is referred to herein as "Compound 1 benzoic acid salt", "Compound 1 benzoic acid" or "Compound 1 benzoate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide benzoate.
[0076] In some embodiments, the salt of the present invention is a benzenesulfonate salt of Compound 1. In some embodiments, the benzenesulfonate salt of Compound 1 is a monobenzenesulfonate salt. In some embodiments, the benzenesulfonate salt of Compound 1 is a dibenzenesulfonate salt. The benzenesulfonate salt form of Compound 1 is referred to herein as "Compound 1 benzenesulfonic acidsalt", "Compound 1 benzenesulfonic acid" or "Compound 1 besylate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide benzenesulfonate.
[0077] In some embodiments, the salt of the present invention is the L-pyroglutamate salt of Compound 1. In some embodiments, the L-pyroglutamate salt of Compound 1 is mono-L-pyroglutamate. In some embodiments, the L-pyroglutamate salt of Compound 1 is di-L-pyroglutamate. The L-pyroglutamate salt form of Compound 1 is referred to herein as "Compound 1 L-pyroglutamate", "Compound 1 L-pyroglutamic acid" or "Compound 1 L-pyroglutamate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide L-pyroglutamate.
[0078] In some embodiments, the salt of the present invention is a methanesulfonate salt of Compound 1. In some embodiments, the methanesulfonate salt of Compound 1 is in the form of a monomethanesulfonate salt. In some embodiments, the methanesulfonate salt of Compound 1 is in the form of a dimethanesulfonate salt. The methanesulfonate salt form of Compound 1 is referred to herein as "Compound 1 methanesulfonic acid salt", "Compound 1 methanesulfonic acid" or "Compound 1 mesylate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide methanesulfonate.
[0079] In some embodiments, the salt of the present invention is a (1S)-(+)-10-camphorsulfonic acid salt of Compound 1. In some embodiments, the (1S)-(+)-10-camphorsulfonic acid salt of Compound 1 is a mono(1S)-(+)-10-camphorsulfonic acid salt. In some embodiments, the (1S)-(+)-10-camphorsulfonic acid salt of Compound 1 is a di(1S)-(+)-10-camphorsulfonic acid salt. The (1S)-(+)-10-camphorsulfonic acid salt form of Compound 1 is referred to herein as "Compound 1 (1S)-(+)-10-camphorsulfonic acid salt", "Compound 1 (1S)-(+)-10-camphorsulfonic acid" or "Compound 1 camsylate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide camphorsulfonate.
[0080] In some embodiments, the salt of the invention is the fumaric acid (trans-butenedioic acid) salt of Compound 1. The fumaric acid salt form of Compound 1 is referred to herein as "Compound 1 fumaric acid salt," "Compound 1 fumaric acid," or "Compound 1 fumarate." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide fumarate.
[0081] In some embodiments, the salt of the present invention is a sulfate salt of Compound 1. In some embodiments, the sulfate salt of Compound 1 is a monosulfate salt. The sulfate salt form of Compound 1 is referred to herein as "Compound 1 sulfuric acid salt", "Compound 1 sulfuric acid" or "Compound 1 sulfate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide sulfate.
[0082] In some embodiments, the salt of the invention is a tartrate salt of Compound 1, such as an L-tartrate salt form. The L-tartrate salt form of Compound 1 is referred to herein as "Compound 1 L-tartrate salt", "Compound 1 L-tartaric acid" or "Compound 1 L-tartrate". An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide L-tartrate.
[0083] In some embodiments, the tartrate salt of Compound 1 is a D-tartrate salt of Compound 1. The D-tartrate salt form of Compound 1 is referred to herein as "Compound 1 D-tartaric acid salt," "Compound 1 D-tartaric acid," or "Compound 1 D-tartrate." An alternative name for the salt is N-{(R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropicolinamide D-tartrate.
[0084] The salts of the present invention can be isolated in one or more solid forms. As used herein, the phrase "solid form" refers to a salt of the present invention in an amorphous or crystalline state ("crystalline form" or "crystalline solid"), wherein the salt of the present invention in a crystalline state may optionally include a solvent or water in the crystal lattice, for example to form a solvated or hydrated crystalline form. As used herein, the term "hydrated" means a crystalline form that includes water molecules in the crystal lattice. Example "hydrated" crystalline forms include hemihydrates, monohydrates, dihydrates, etc. Other hydrated forms such as channel-type hydrates are also included in the meaning of this term.
[0085] The different crystalline forms of the salts of the present invention are characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and / or thermogravimetric analysis (TGA). The X-ray powder diffraction (XRPD) pattern of reflections (peaks) is typically considered to be the fingerprint of a specific crystalline form. It is well known that the relative intensities of XRPD peaks can vary widely, particularly depending on sample preparation techniques, crystal size distribution, the various filters used, the sample installation procedure, and the specific instrument employed. In some cases, new peaks may be observed, or existing peaks may disappear, depending on the instrument type or environment (e.g., whether a Ni filter is used or not). As used herein, the term "peak" or "characteristic peak" refers to a reflection whose relative height / intensity is at least about 3% of the maximum peak height / intensity. In addition, instrument deviations and other factors may affect 2θ values. Therefore, peak assignments, such as those reported herein, may vary by ± about 0.2° (2θ), and the terms "substantially" or "about" as used herein in the context of XRPD refer to the above deviations.
[0086] In like manner, temperature readings associated with DSC, TGA or other thermal experiments may vary by about ±3°C, depending on the instrument, specific circumstances, sample preparation, etc. Thus, it is to be understood that a crystalline form reported herein as having a DSC thermogram "substantially" as shown in any of the Figures is subject to such variations.
[0087] Salts and compounds disclosed herein may include all isotopes of atoms present therein. Isotopes include those atoms with the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. Salts and compounds of the present invention may also include all isotopes of atoms present in intermediates or final compounds. Isotopes include those atoms with the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the compounds of the present invention may be replaced or substituted by isotopes of atoms of natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in the compounds of the present disclosure may be replaced or substituted by deuterium. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7 or 8 deuterium atoms. Synthetic methods for incorporating isotopes into organic compounds are known in the art.
[0088] In some embodiments, the compounds of the present invention or their salts are substantially separated. "Substantially separated" means that the compound or salt is at least partially or substantially separated from the environment in which it is formed or detected. Partial separation can include, for example, a composition rich in the compounds of the present invention. Substantially separated can include a composition containing at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the compounds of the present invention or salts.
[0089] The phrase "pharmaceutically acceptable" as used herein refers to those compounds, substances, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0090] As used herein, the term "melting point" refers to an endothermic event observed, for example, in a DSC experiment. An endothermic event is a process or reaction in which a sample absorbs energy from its surroundings, for example, in the form of heat in a DSC experiment. An exothermic event is a process or reaction in which a sample releases energy. Endothermic and exothermic processes can be detected by DSC. In some embodiments, the term "melting point" is used to describe the main endothermic event revealed on a specific DSC thermogram.
[0091] As used herein, the term "room temperature" is understood in the art and generally refers to a temperature approximately equal to the temperature of the space in which the reaction is carried out, such as a reaction temperature, for example, a temperature of about 20°C to about 30°C.
[0092] As used herein, the term "elevated temperature" is understood in the art and generally refers to temperatures above room temperature, such as above 30°C, such as reaction temperatures.
[0093] Phosphate
[0094] The present invention is particularly directed to phosphate salts of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, such as the salt shown below.
[0095]
[0096] Compound 1 phosphate can be made into an amorphous solid, a crystalline solid, or a mixture thereof. In some embodiments, the crystalline solid has form I, which is described in the following examples. In some embodiments, the crystalline solid of form I has a characteristic XRPD peak at about 4.6° according to 2θ. In some embodiments, the crystalline solid of form I has at least one characteristic XRPD peak at about 4.6° or about 9.4° according to 2θ. In some embodiments, the crystalline solid of form I has at least one characteristic XRPD peak at about 4.6°, about 9.4°, or about 13.1° according to 2θ. In some embodiments, the crystalline solid of form I has two or more than two characteristic XRPD peaks selected from the following according to 2θ: about 4.6°, about 9.4°, about 13.1°, about 16.2°, about 17.4°, about 17.9°, about 18.8°, about 19.4°, about 21.1°, about 23.0°, and about 24.8°. In some embodiments, the crystalline solid of Form I has three or more characteristic XRPD peaks according to 2θ selected from the group consisting of about 4.6°, about 9.4°, about 13.1°, about 16.2°, about 17.4°, about 17.9°, about 18.8°, about 19.4°, about 21.1°, about 23.0°, about 24.8°, and about 25.2°. In some embodiments, the crystalline solid of Form I has four or more characteristic XRPD peaks according to 2θ selected from the group consisting of about 4.6°, about 9.4°, about 13.1°, about 16.2°, about 17.4°, about 17.9°, about 18.8°, about 19.4°, about 21.1°, about 23.0°, about 24.8°, and about 25.2°. In some embodiments, the crystalline solid of Form I has substantially Figure 1 In some embodiments, the melting point of the crystalline solid of Form I is about 250°C. In some embodiments, the endothermic event of the crystalline solid of Form I is at about 198°C or about 250°C. In some embodiments, the crystalline solid of Form I has substantially Figure 2 In some embodiments, the crystalline solid of Form I has substantially Figure 3 TGA thermogram depicted in .
[0097] Advantages of phosphate salts include high crystallinity, high melting point, stable crystalline form (eg, Form I), and non-hygroscopic properties, each of which facilitates purification, reproducibility, scale-up, manufacturing, and formulation of pharmaceutical compounds.
[0098] In some embodiments, the phosphate salt of compound 1 is a crystalline solid having form II. In some embodiments, the crystalline solid having form II has at least one characteristic XRPD peak selected from the following according to 2θ: about 4.7°, about 9.4°, about 18.8°, about 21.7°, about 24.8°, and about 33.3°. In some embodiments, the crystalline solid having form II has at least 2 characteristic XRPD peaks selected from the following according to 2θ: about 4.7°, about 9.4°, about 18.8°, about 21.7°, about 24.8°, and about 33.3°. In some embodiments, the crystalline solid having form II has at least 3 characteristic XRPD peaks selected from the following according to 2θ: about 4.7°, about 9.4°, about 18.8°, about 21.7°, about 24.8°, and about 33.3°. In some embodiments, the crystalline solid of Form II has at least one characteristic XRPD peak according to 2θ selected from the group consisting of: about 4.7°, about 9.4°, about 18.8°. In some embodiments, the crystalline solid of Form II has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of: about 4.7°, about 9.4°, about 18.8°. In some embodiments, the crystalline solid of Form II has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of: about 4.7°, about 9.4°, about 18.8°. Figure 7 In some embodiments, the melting point of the crystalline solid having Form II is about 249° C. In some embodiments, the endothermic event of the crystalline solid having Form II is at about 249° C. In some embodiments, the crystalline solid having Form II has substantially Figure 8 In some embodiments, the crystalline solid having Form II has substantially Fig. 9 TGA thermogram depicted in .
[0099] In some embodiments, the phosphate salt of compound 1 is a crystalline solid of form III. In some embodiments, the crystalline solid of form III has at least one characteristic XRPD peak selected from the group consisting of about 4.6°, about 9.4°, about 13.3°, about 16.3°, about 18.9°, about 19.2°, about 21.2°, about 22.5°, about 23.1°, about 24.9°, and about 26.7°, according to 2θ. In some embodiments, the crystalline solid of form III has at least two characteristic XRPD peaks selected from the group consisting of about 4.6°, about 9.4°, about 13.3°, about 16.3°, about 18.9°, about 19.2°, about 21.2°, about 22.5°, about 23.1°, about 24.9°, and about 26.7°, according to 2θ. In some embodiments, the crystalline solid having form III has at least three characteristic XRPD peaks according to 2θ selected from the group consisting of about 4.6°, about 9.4°, about 13.3°, about 16.3°, about 18.9°, about 19.2°, about 21.2°, about 22.5°, about 23.1°, about 24.9°, and about 26.7°. In some embodiments, the crystalline solid having form III has at least one characteristic XRPD peak according to 2θ selected from the group consisting of about 4.6°, about 18.9°, about 19.2°, about 22.5°, and about 23.1°. In some embodiments, the crystalline solid having form III has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of about 4.6°, about 18.9°, about 19.2°, about 22.5°, and about 23.1°. In some embodiments, the crystalline solid having Form III has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 4.6°, about 18.9°, about 19.2°, about 22.5°, and about 23.1°. ... Fig.10 In some embodiments, the melting point of the crystalline solid having Form III is about 250° C. In some embodiments, the endothermic event of the crystalline solid having Form III is at about 250° C. In some embodiments, the crystalline solid having Form III has substantially Fig.11 In some embodiments, the crystalline solid having form III has substantially Fig.12 TGA thermogram depicted in .
[0100] In some embodiments, the phosphate salt of Compound 1 is a crystalline solid of Form IV. In some embodiments, the crystalline solid of Form IV has at least one characteristic XRPD peak selected from the group consisting of about 4.1°, about 13.3°, about 16.4°, about 17.7°, about 18.6°, about 19.8°, about 21.4°, and about 23.3°, according to 2θ. In some embodiments, the crystalline solid of Form IV has at least two characteristic XRPD peaks selected from the group consisting of about 4.1°, about 13.3°, about 16.4°, about 17.7°, about 18.6°, about 19.8°, about 21.4°, and about 23.3°, according to 2θ. In some embodiments, the crystalline solid having form IV has at least three characteristic XRPD peaks according to 2θ selected from the group consisting of about 4.1°, about 13.3°, about 16.4°, about 17.7°, about 18.6°, about 19.8°, about 21.4°, and about 23.3°. In some embodiments, the crystalline solid having form IV has at least one characteristic XRPD peak according to 2θ selected from the group consisting of about 4.1°, about 13.3°, about 16.4°, about 18.6°, about 19.8°, and about 21.4°. In some embodiments, the crystalline solid having form IV has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of about 4.1°, about 13.3°, about 16.4°, about 18.6°, about 19.8°, and about 21.4°. In some embodiments, the crystalline solid having Form IV has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 4.1°, about 13.3°, about 16.4°, about 18.6°, about 19.8°, and about 21.4°. ... Fig.13 In some embodiments, the melting point of the crystalline solid having form IV is about 245° C. In some embodiments, the melting point of the crystalline solid having form IV is about 245° C. In some embodiments, the crystalline solid having form IV has a substantially Fig.14 In some embodiments, the crystalline solid having form IV has substantially Fig.15 TGA thermogram depicted in .
[0101] In some embodiments, the phosphate salt of Compound 1 is a crystalline solid having Form V. In some embodiments, the crystalline solid having Form V has at least one characteristic XRPD peak according to 2θ selected from the group consisting of about 7.3°, about 10.9°, about 16.4°, about 18.5°, about 19.8°, about 22.6°, and about 26.1°. In some embodiments, the crystalline solid having Form V has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of about 7.3°, about 10.9°, about 16.4°, about 18.5°, about 19.8°, about 22.6°, and about 26.1°. In some embodiments, the crystalline solid having Form V has at least three characteristic XRPD peaks according to 2θ selected from the group consisting of about 7.3°, about 10.9°, about 16.4°, about 18.5°, about 19.8°, about 22.6°, and about 26.1°. In some embodiments, the crystalline solid having Form V has at least one characteristic XRPD peak according to 2θ selected from the group consisting of: about 7.3°, about 10.9°, about 16.4°, about 18.5°, and about 19.8°. In some embodiments, the crystalline solid having Form V has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of: about 7.3°, about 10.9°, about 16.4°, about 18.5°, and about 19.8°. In some embodiments, the crystalline solid having Form V has at least three characteristic XRPD peaks according to 2θ selected from the group consisting of: about 7.3°, about 10.9°, about 16.4°, about 18.5°, and about 19.8°. In some embodiments, the crystalline solid having Form V has at least three characteristic XRPD peaks according to 2θ selected from the group consisting of: about 7.3°, about 10.9°, about 16.4°, about 18.5°, and about 19.8°. Fig.16 In some embodiments, the endothermic event of the crystalline solid having Form V is at about 95° C. or about 245° C. In some embodiments, the crystalline solid having Form V has substantially Fig.17 In some embodiments, the crystalline solid having Form V has substantially Fig.18 TGA thermogram depicted in .
[0102] In some embodiments, the phosphate salt of Compound 1 is a crystalline solid of Form VI. In some embodiments, the crystalline solid of Form VI has at least one characteristic XRPD peak selected from the group consisting of about 6.5°, about 8.3°, about 10.7°, about 13.2°, about 17.3°, and about 19.1°, according to 2θ. In some embodiments, the crystalline solid of Form VI has at least two characteristic XRPD peaks selected from the group consisting of about 6.5°, about 8.3°, about 10.7°, about 13.2°, about 17.3°, and about 19.1°, according to 2θ. In some embodiments, the crystalline solid of Form VI has at least three characteristic XRPD peaks selected from the group consisting of about 6.5°, about 8.3°, about 10.7°, about 13.2°, about 17.3°, and about 19.1°, according to 2θ. In some embodiments, the crystalline solid of Form VI has at least one characteristic XRPD peak according to 2θ selected from the group consisting of: about 6.5°, about 8.3°, and about 10.7°. In some embodiments, the crystalline solid of Form VI has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of: about 6.5°, about 8.3°, and about 10.7°. In some embodiments, the crystalline solid of Form VI has at least two characteristic XRPD peaks according to 2θ selected from the group consisting of: about 6.5°, about 8.3°, and about 10.7°. Fig.19 In some embodiments, the melting point of the crystalline solid having Form VI is about 86°C. In some embodiments, the endothermic event of the crystalline solid having Form VI is at about 86°C or about 221°C. In some embodiments, the crystalline solid having Form VI has substantially Fig. 20 In some embodiments, the crystalline solid having form VI has substantially Fig.21 TGA thermogram depicted in .
[0103] In some embodiments, the present invention provides a mixture of crystalline solid Form I with one or more solid forms selected from the group consisting of amorphous, Form II, Form III, Form IV, and Form V. In some embodiments, the mixture of crystalline solid Form I has greater than about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, or about 99% Form I.
[0104] In some embodiments, the crystalline solid Form I is prepared in high purity. The purity value indicates the percentage of the amount of Form I in the sample. The purity value can be determined, for example, by HPLC / UV method. In some embodiments, Form I has a purity of greater than about 90%, greater than about 95%, greater than about 97%, greater than about 98%, or greater than about 99%. In some embodiments, Form I is substantially free of impurities, such as organic impurities, inorganic impurities, and / or residual solvents. Examples of organic impurities include, for example, starting materials and process intermediates, such as
[0105] Examples of organic impurities include, for example, process impurities, e.g.
[0106] Examples of inorganic impurities include, for example, heavy metals, palladium, and ruthenium. Examples of residual solvents include, for example, acetonitrile, dichloromethane, N,N-dimethylformamide, 1,4-dioxane, n-heptane, methanol, and 2-propanol.
[0107] Hydrochloride
[0108] The present invention further provides a dihydrochloride salt of Compound 1. In some embodiments, the solid form of the dihydrochloride salt has Figure 4 In some embodiments, the solid form of the dihydrochloride salt has a melting point of about 213°C. In some embodiments, the endothermic event of the solid form of the dihydrochloride salt is at about 213°C. In some embodiments, the solid form of the dihydrochloride salt is characterized by being substantially as follows Figure 5 In some embodiments, the solid form of the dihydrochloride salt is characterized by being substantially as follows Figure 6 TGA thermogram depicted in .
[0109] In some embodiments, the dihydrochloride salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the dihydrochloride salt of Compound 1 has at least one characteristic XRPD peak selected from the group consisting of about 8.3°, about 18.9°, and about 25.0°, according to 2θ. In some embodiments, the crystalline solid of the dihydrochloride salt of Compound 1 has two or more characteristic XRPD peaks selected from the group consisting of about 8.3°, about 18.9°, and about 25.0°, according to 2θ.
[0110] The present invention further provides a monohydrochloride salt of Compound 1. In some embodiments, the solid form of the monohydrochloride salt has a Fig. 22 In some embodiments, the melting point of the solid form of the monohydrochloride salt is about 209°C. In some embodiments, the endothermic event of the solid form of the monohydrochloride salt is at about 209°C. In some embodiments, the solid form of the monohydrochloride salt is characterized by being substantially as follows Fig.23 DSC thermogram depicted in .
[0111] In some embodiments, the monohydrochloride salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the monohydrochloride salt of Compound 1 has at least one characteristic XRPD peak selected from the group consisting of about 7.8°, about 8.8°, about 12.6°, about 14.5°, about 17.4°, about 23.8°, and about 25.2° according to 2θ. In some embodiments, the crystalline solid of the monohydrochloride salt of Compound 1 has two or more characteristic XRPD peaks selected from the group consisting of about 7.8°, about 8.8°, about 12.6°, about 14.5°, about 17.4°, about 23.8°, and about 25.2° according to 2θ. In some embodiments, the crystalline solid of the monohydrochloride salt of Compound 1 has three or more characteristic XRPD peaks selected from the group consisting of about 7.8°, about 8.8°, about 12.6°, about 14.5°, about 17.4°, about 23.8°, and about 25.2° according to 2θ.
[0112] Maleate
[0113] The present invention further provides a maleic acid salt of Compound 1. In some embodiments, the solid form of the maleic acid salt has Fig.24 In some embodiments, the solid form of the maleate salt has a melting point of about 202°C. In some embodiments, the endothermic event of the solid form of the maleate salt is at about 202°C. In some embodiments, the solid form of the maleate salt has a substantially Fig.25 In some embodiments, the maleate salt has substantially Fig.26 TGA thermogram depicted in .
[0114] In some embodiments, the maleic acid salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the maleic acid salt of Compound 1 has at least one characteristic XRPD peak, based on 2θ, selected from the group consisting of: about 9.0°, about 9.5°, about 11.2°, about 14.8°, about 15.9°, about 18.5°, about 19.5°, about 19.9°, about 21.3°, about 22.9°, about 24.8°, about 25.8°, about 27.6°, and about 30.9°. In some embodiments, the crystalline solid of the maleic acid salt of Compound 1 has at least two characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 9.0°, about 9.5°, about 11.2°, about 14.8°, about 15.9°, about 18.5°, about 19.5°, about 19.9°, about 21.3°, about 22.9°, about 24.8°, about 25.8°, about 27.6°, and about 30.9°. In some embodiments, the crystalline solid of the maleic acid salt of Compound 1 has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 9.0°, about 9.5°, about 11.2°, about 14.8°, about 15.9°, about 18.5°, about 19.5°, about 19.9°, about 21.3°, about 22.9°, about 24.8°, about 25.8°, about 27.6°, and about 30.9°.
[0115] Adipate
[0116] The present invention further provides an adipate salt of Compound 1. In some embodiments, the solid form of the adipate salt has a Fig. 27 In some embodiments, the solid form of the adipate salt has a melting point of about 182°C. In some embodiments, the endothermic event of the solid form of the adipate salt is at about 150°C or about 182°C. In some embodiments, the solid form of the adipate salt has a substantially Fig.28 In some embodiments, the adipate salt has substantially Fig.29 TGA thermogram depicted in .
[0117] In some embodiments, the adipate salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the adipate salt of Compound 1 has at least one characteristic XRPD peak selected from the group consisting of about 9.3°, about 15.0°, about 16.2°, about 17.6°, about 18.7°, about 20.0°, about 22.1°, about 22.7°, about 24.3°, about 24.9°, about 27.1°, and about 28.7°, according to 2θ. In some embodiments, the crystalline solid of the adipate salt of Compound 1 has at least two characteristic XRPD peaks selected from the group consisting of about 9.3°, about 15.0°, about 16.2°, about 17.6°, about 18.7°, about 20.0°, about 22.1°, about 22.7°, about 24.3°, about 24.9°, about 27.1°, and about 28.7°, according to 2θ. In some embodiments, the crystalline solid of the adipate salt of Compound 1 has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 9.3°, about 15.0°, about 16.2°, about 17.6°, about 18.7°, about 20.0°, about 22.1°, about 22.7°, about 24.3°, about 24.9°, about 27.1°, and about 28.7°.
[0118] Hydrobromide
[0119] The present invention further provides a hydrobromide salt of Compound 1. In some embodiments, the solid form of the hydrobromide salt has a Fig.32 In some embodiments, the solid form of the hydrobromide salt has a melting point of about 247° C. In some embodiments, the solid form of the hydrobromide salt has a substantially Fig.33 In some embodiments, the solid form of the hydrobromide salt has substantially Fig.34 TGA thermogram depicted in .
[0120] In some embodiments, the hydrobromide salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the hydrobromide salt of Compound 1 has at least one characteristic XRPD peak selected from the group consisting of about 6.5°, about 9.5°, about 12.9°, about 16.6°, about 17.9°, about 19.5°, about 21.7°, about 22.5°, about 23.7°, about 24.3°, about 26.5°, about 27.5°, and about 28.3°, according to 2θ. In some embodiments, the crystalline solid of the hydrobromide salt of Compound 1 has at least two characteristic XRPD peaks selected from the group consisting of about 6.5°, about 9.5°, about 12.9°, about 16.6°, about 17.9°, about 19.5°, about 21.7°, about 22.5°, about 23.7°, about 24.3°, about 26.5°, about 27.5°, and about 28.3°, according to 2θ. In some embodiments, the crystalline solid of the hydrobromide salt of Compound 1 has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 6.5°, about 9.5°, about 12.9°, about 16.6°, about 17.9°, about 19.5°, about 21.7°, about 22.5°, about 23.7°, about 24.3°, about 26.5°, about 27.5°, and about 28.3°.
[0121] (R)-(-)-Mandelate
[0122] The present invention further provides a (R)-(-)-mandelate salt of Compound 1. In some embodiments, the solid form of the (R)-(-)-mandelate salt has a Fig.33 In some embodiments, the solid form of the (R)-(-)-mandelate salt has a melting point of about 224°C. In some embodiments, the solid form of the (R)-(-)-mandelate salt has an endothermic event at about 223°C or about 225°C. In some embodiments, the solid form of the (R)-(-)-mandelate salt has a substantially Fig.34 In some embodiments, the solid form of the (R)-(-)-mandelate salt has substantially Fig.35 TGA thermogram depicted in .
[0123] In some embodiments, the (R)-(-)-mandelate salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the (R)-(-)-mandelate salt of Compound 1 has at least one characteristic XRPD peak selected from the group consisting of about 11.2°, about 13.8°, about 18.6°, about 20.6°, about 22.5°, and about 24.1°, according to 2θ. In some embodiments, the crystalline solid of the (R)-(-)-mandelate salt of Compound 1 has at least two characteristic XRPD peaks selected from the group consisting of about 11.2°, about 13.8°, about 18.6°, about 20.6°, about 22.5°, and about 24.1°, according to 2θ. In some embodiments, the crystalline solid of the (R)-(-)-mandelate salt of Compound 1 has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 11.2°, about 13.8°, about 18.6°, about 20.6°, about 22.5°, and about 24.1°.
[0124] Salicylates
[0125] In some embodiments, the salt of Compound 1 is a salicylate. In some embodiments, the solid form of the salicylate has a Fig.36 In some embodiments, the solid form of the salicylate has an endothermic event at about 180°C or about 208°C. In some embodiments, the solid form of the salicylate has a substantially Fig.37 DSC thermogram depicted in .
[0126] In some embodiments, the salicylate of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the salicylate of Compound 1 has at least one characteristic XRPD peak selected from the group consisting of about 21.2° and about 23.5° according to 2θ. In some embodiments, the crystalline solid of the salicylate of Compound 1 has at least one characteristic XRPD peak selected from the group consisting of about 11.8°, about 16.7°, about 18.7°, about 21.2°, about 21.9°, about 23.0°, about 23.5°, and about 24.1° according to 2θ. In some embodiments, the crystalline solid of the salicylate of Compound 1 has at least two characteristic XRPD peaks selected from the group consisting of about 11.8°, about 16.7°, about 18.7°, about 21.2°, about 21.9°, about 23.0°, about 23.5°, and about 24.1° according to 2θ. In some embodiments, the crystalline solid of Compound 1 salicylate has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 11.8°, about 16.7°, about 18.7°, about 21.2°, about 21.9°, about 23.0°, about 23.5°, and about 24.1°.
[0127] Other salts
[0128] The present invention further provides a benzoate salt of Compound 1. In some embodiments, the solid form of the benzoate salt has a Fig.38 The XRPD pattern shown above. In some embodiments, the benzoate salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the benzoate salt of Compound 1 has at least one characteristic XRPD peak selected from the following according to 2θ: about 11.6°, about 14.9°, about 16.9°, about 18.8°, about 21.5°, about 23.2°, about 23.7°, and about 24.9°. In some embodiments, the crystalline solid of the benzoate salt of Compound 1 has at least two characteristic XRPD peaks selected from the following according to 2θ: about 11.6°, about 14.9°, about 16.9°, about 18.8°, about 21.5°, about 23.2°, about 23.7°, and about 24.9°. In some embodiments, the crystalline solid of the benzoate salt of Compound 1 has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 11.6°, about 14.9°, about 16.9°, about 18.8°, about 21.5°, about 23.2°, about 23.7°, and about 24.9°.
[0129] The present invention further provides a benzenesulfonate salt of Compound 1. In some embodiments, the solid form of the benzenesulfonate salt has a Fig.39 The XRPD pattern shown above. In some embodiments, the besylate salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the besylate salt of Compound 1 has at least one characteristic XRPD peak selected from the following according to 2θ: about 6.6°, about 9.1°, about 12.9°, about 13.3°, about 14.5°, about 18.0°, about 23.5°, and about 23.9°. In some embodiments, the crystalline solid of the besylate salt of Compound 1 has at least two characteristic XRPD peaks selected from the following according to 2θ: about 6.6°, about 9.1°, about 12.9°, about 13.3°, about 14.5°, about 18.0°, about 23.5°, and about 23.9°. In some embodiments, the crystalline solid of the besylate salt of Compound 1 has at least three characteristic XRPD peaks, in terms of 2θ, selected from the group consisting of: about 6.6°, about 9.1°, about 12.9°, about 13.3°, about 14.5°, about 18.0°, about 23.5°, and about 23.9°.
[0130] The present invention further provides an L-pyroglutamate salt of Compound 1. In some embodiments, the solid form of the L-pyroglutamate salt has Fig.40The XRPD pattern shown above. In some embodiments, the L-pyroglutamate salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the L-pyroglutamate salt of Compound 1 has at least one characteristic XRPD peak selected from the following according to 2θ: about 4.4°, about 10.7°, about 11.5°, about 18.0°, about 20.7°, about 21.2°, and about 22.9°. In some embodiments, the crystalline solid of the L-pyroglutamate salt of Compound 1 has at least two characteristic XRPD peaks selected from the following according to 2θ: about 4.4°, about 10.7°, about 11.5°, about 18.0°, about 20.7°, about 21.2°, and about 22.9°. In some embodiments, the crystalline solid of Compound 1 L-pyroglutamate has at least three characteristic XRPD peaks, in terms of 2θ, selected from the group consisting of: about 4.4°, about 10.7°, about 11.5°, about 18.0°, about 20.7°, about 21.2°, and about 22.9°.
[0131] The present invention further provides a mesylate salt of Compound 1. In some embodiments, the solid form of the mesylate salt has a Fig.41 The XRPD pattern shown above. In some embodiments, the mesylate salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the mesylate salt of Compound 1 has at least one characteristic XRPD peak selected from the following according to 2θ: about 13.5°, about 14.7°, about 16.7°, about 18.6°, about 19.3°, about 20.0°, about 20.7°, about 22.4°, about 25.7°, about 26.8°, about 27.2°, and about 28.1°. In some embodiments, the crystalline solid of the mesylate salt of Compound 1 has at least two characteristic XRPD peaks selected from the following according to 2θ: about 13.5°, about 14.7°, about 16.7°, about 18.6°, about 19.3°, about 20.0°, about 20.7°, about 22.4°, about 25.7°, about 26.8°, about 27.2°, and about 28.1°. In some embodiments, the crystalline solid of the mesylate salt of Compound 1 has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 13.5°, about 14.7°, about 16.7°, about 18.6°, about 19.3°, about 20.0°, about 20.7°, about 22.4°, about 25.7°, about 26.8°, about 27.2°, and about 28.1°.
[0132] The present invention further provides a (1S)-(+)-10-camphorsulfonate salt of Compound 1. In some embodiments, the solid form of the (1S)-(+)-10-camphorsulfonate salt has a Fig.42The XRPD pattern shown above. In some embodiments, the (1S)-(+)-10-camsylate salt of Compound 1 is a crystalline solid. In some embodiments, the crystalline solid of the (1S)-(+)-10-camsylate salt of Compound 1 has at least one characteristic XRPD peak selected from the following according to 2θ: about 7.1°, about 10.9°, about 13.6°, about 16.1°, about 17.7°, about 18.8°, about 19.9°, and about 23.2°. In some embodiments, the crystalline solid of the (1S)-(+)-10-camsylate salt of Compound 1 has at least two characteristic XRPD peaks selected from the following according to 2θ: about 7.1°, about 10.9°, about 13.6°, about 16.1°, about 17.7°, about 18.8°, about 19.9°, and about 23.2°. In some embodiments, the crystalline solid of Compound 1 (1S)-(+)-10-camsylate salt has at least three characteristic XRPD peaks, based on 2θ, selected from the group consisting of: about 7.1°, about 10.9°, about 13.6°, about 16.1°, about 17.7°, about 18.8°, about 19.9°, and about 23.2°.
[0133] The present invention further provides fumarate salts. In some embodiments, the solid form of the fumarate salt has Fig.43 The XRPD pattern is shown above. In some embodiments, the fumarate salt is amorphous.
[0134] The present invention further provides a sulfate salt of Compound 1. In some embodiments, the solid form of the sulfate salt has Fig.44 The XRPD pattern is shown above. In some embodiments, the sulfate salt is amorphous.
[0135] The present invention further provides an L-tartrate salt of Compound 1. In some embodiments, the L-tartrate salt is amorphous. The solid form of the L-tartrate salt has Fig.45 The XRPD pattern shown in .
[0136] The present invention further provides a D-tartrate salt of Compound 1. In some embodiments, the D-tartrate salt is amorphous. The solid form of the L-tartrate salt has Fig.46 The XRPD pattern shown in .
[0137] Synthesis of phosphates
[0138] In general, the phosphate salts of the present invention can be prepared by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (referred to herein as "Compound 1" or "Compound 1 free base") with phosphoric acid. In some embodiments, phosphoric acid is provided in a molar excess relative to the free base of Compound 1. In some embodiments, the combination of Compound 1 free base and phosphoric acid is carried out in the presence of a solvent. In some embodiments, the solvent comprises water, methanol, 2-propanol, or a mixture thereof. In some embodiments, the combination can be carried out at an elevated temperature, for example, from about 40°C to about 80°C, from about 50°C to about 70°C, or from about 55°C to about 65°C. In some embodiments, the Compound 1 phosphate product obtained from the combination is substantially crystalline. In some embodiments, the crystalline product comprises one or more of Forms I, II, III, IV, V, and VI. In some embodiments, the crystalline product comprises Form I. In some embodiments, the crystalline product comprises substantially Form I. In some embodiments, the Compound 1 phosphate product obtained from combining phosphoric acid with Compound 1 is substantially amorphous or contains amorphous solids.
[0139] Compound 1 free base (a precursor of the phosphate salt) can be prepared by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide dihydrochloride (referred to herein as "Compound 1 dihydrochloride" or "Compound 1 dihydrochloride") with sodium carbonate. In some embodiments, sodium carbonate is provided in a molar excess relative to Compound 1 dihydrochloride. In some embodiments, the combination of Compound 1 dihydrochloride and sodium carbonate is carried out in the presence of a solvent. In some embodiments, the solvent comprises water, dichloromethane, or a mixture thereof. In some embodiments, the combination is carried out at room temperature or at an elevated temperature. Exemplary reaction temperatures include about 20°C to about 40°C, about 20°C to about 30°C, and about 23°C to about 27°C.
[0140] Compound 1 dihydrochloride can be prepared by reacting tert-butyl {(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-[(7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-({[6-(2,6-difluorophenyl)-5-fluoropyridin-2-yl]carbonyl}amino)-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl]-5-methylpiperidin-3-yl}carbamate (25):
[0141]
[0142] In some embodiments, the reaction with hydrogen chloride is carried out in the presence of a solvent. In some embodiments, the solvent comprises 1,4-dioxane, methanol or a mixture thereof. In some embodiments, the reaction with hydrogen chloride is carried out at room temperature.
[0143] Intermediate (25) can be prepared by the reaction of tert-butyl ((3R,4R,5S)-1-(3-amino-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate:
[0144]
[0145] With 6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxylic acid:
[0146]
[0147] In some embodiments, (24) is provided in a slight molar excess relative to (23) (e.g., about 1.1 to about 1.5 equivalents or about 1.2 equivalents). In some embodiments, the coupling is carried out in the presence of N,N-diisopropylethylamine (DIEA) and N,N,N',N'-tetramethyl-O-(7-azabenzotriazole-1-yl)uronium hexafluorophosphate (HATU). In some embodiments, DIEA is provided in a molar excess relative to (23) (e.g., about 3 to 6 equivalents or about 5 equivalents). In some embodiments, HATU is provided in a molar excess relative to (23) (e.g., about 1.5 to 3.5 equivalents or about 2.4 equivalents). In other embodiments, the coupling is carried out in the presence of a solvent. In some embodiments, the solvent comprises dimethylformamide (DMF). In some embodiments, the coupling is carried out at about 10°C to about 40°C or about 15°C to about 30°C.
[0148] Intermediate (23) can be prepared by reacting tert-butyl ((3R,4R,5S)-1-((7R)-3-(aminocarbonyl)-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate:
[0149]
[0150] Prepared by mixing with tetra-N-butylammonium bromide (TBAB) in the presence of sodium hydroxide. In some embodiments, TBAB is provided in an amount of about 1 equivalent relative to (22). In some embodiments, sodium hydroxide is provided in a molar excess relative to (22) (e.g., about 1.1 to about 7 equivalents or about 2 to about 4 equivalents, or about 4.5 equivalents). In some embodiments, mixing is carried out in the presence of 1,3-dibromo-5,5-dimethylhydantoin. In some embodiments, the amount of 1,3-dibromo-5,5-dimethylhydantoin provided is less than 1 equivalent relative to (22) (e.g., about 0.1 to about 0.9 equivalents or about 0.3 to about 0.8 equivalents or about 0.7 equivalents). In some embodiments, mixing is carried out in the presence of a solvent. In some embodiments, the solvent comprises tetrahydrofuran (THF). In some embodiments, mixing is carried out at a temperature below room temperature, for example, at about 0°C to about 20°C, about 0°C to about 15°C, or about 5°C to about 10°C.
[0151] Intermediate (22) can be prepared by reacting tert-butyl [(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-((7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-cyano-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-5-methylpiperidin-3-yl]carbamate:
[0152]
[0153] Prepared by reaction with acetaldehyde oxime. In some embodiments, the reaction with acetaldehyde oxime is carried out in the presence of a palladium catalyst (e.g., a complex of [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (Pd(dppf)2Cl2) and dichloromethane). In some embodiments, acetaldehyde oxime is provided in a molar excess (e.g., about 2 to about 20 equivalents, about 5 to about 15 equivalents, or about 10 equivalents). In some embodiments, the total amount of acetaldehyde oxime is delivered to the reaction mixture in portions. In some embodiments, the reaction with acetaldehyde oxime is carried out in the presence of a solvent. In some embodiments, the solvent comprises water, ethanol, or a mixture thereof. In some embodiments, the reaction is carried out at a high temperature (e.g., about 50°C to about 150°C, about 70°C to about 100°C, or about 90°C).
[0154] Intermediate (21) can be prepared by reacting (7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile:
[0155]
[0156] With tert-butyl ((3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate (9) or its hydrochloride (9HCl):
[0157]
[0158] Prepared by reaction in the presence of N,N-diisopropylethylamine (DIEA). In some embodiments, intermediate (9) is provided in a slight molar excess (e.g., 1.05 equivalents) relative to (20). In some embodiments, DIEA is provided in a molar excess (e.g., about 2 to about 6 equivalents or about 4 equivalents) relative to (20). In some embodiments, the reaction of (20) with (9) is carried out in the presence of a solvent. In some embodiments, the solvent comprises dimethyl sulfoxide. In some embodiments, the reaction is carried out at room temperature or at an elevated temperature (e.g., at about 30°C to about 150°C or at about 100°C).
[0159] The intermediate (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile (20) can be prepared by reacting (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbaldehyde (19):
[0160]
[0161] In some embodiments, the reaction is carried out in the presence of a solvent. In some embodiments, the solvent comprises water, THF or a mixture thereof. In some embodiments, the reaction is carried out at a temperature below room temperature, for example, between about 10° C. and 22° C. In some embodiments, ammonia and iodine are provided in molar excess.
[0162] The intermediate (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbaldehyde (19) can be prepared by reacting (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (18):
[0163]
[0164] It is prepared by combining with n-butyl lithium in the presence of 2,2,6,6-tetramethylpiperidine, followed by the addition of N,N-dimethylformamide (DMF). In some embodiments, the combination is carried out at below room temperature, for example, -100°C to -10°C. In some embodiments, the combination is carried out in a solvent. In some embodiments, the solvent comprises THF, hexane, or a mixture thereof.
[0165] The intermediate (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (18) can be prepared by reacting (R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-7-ol (17):
[0166]
[0167] Prepared by reaction with tert-butyldimethylsilyl chloride and 1H-imidazole. In some embodiments, the reaction is carried out at a temperature below room temperature, for example, at about -15°C to 15°C or about -15°C to 0°C. In some embodiments, the reaction is carried out in the presence of a solvent, such as dichloromethane or other organic solvents. In some embodiments, tert-butyldimethylsilyl chloride is provided in an amount of about 1 equivalent relative to (17). In some embodiments, 1H-imidazole is provided in a molar excess relative to (17).
[0168] The intermediate (R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (17) can be prepared by reacting 4-chloro-5H-cyclopenta[b]pyridin-7(6H)-one (16):
[0169]
[0170] Prepared by reacting RuCl(p-cymene)[(R,R)-Ts-DPEN] with formic acid in the presence of RuCl(p-cymene)[(R,R)-Ts-DPEN] and triethylamine (TEA). In some embodiments, the reaction is carried out in the presence of a solvent, such as dichloromethane or other organic solvent. In some embodiments, the reaction is carried out at a temperature below room temperature. In some embodiments, RuCl(p-cymene)[(R,R)-Ts-DPEN] is provided in a catalytic amount. In some embodiments, TEA is provided in a molar excess relative to (16). In some embodiments, formic acid is provided in a molar excess relative to (16).
[0171] The intermediate 4-chloro-5H-cyclopenta[b]pyridin-7(6H)-one (16) can be prepared by reacting 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (15):
[0172]
[0173] Prepared by reaction with pyridine-sulfur trioxide in the presence of N,N-diisopropylethylamine. In some embodiments, (15) and N,N-diisopropylethylamine are combined before adding pyridine-sulfur trioxide. In some embodiments, the reaction is carried out in the presence of a solvent. In some embodiments, the solvent comprises dichloromethane or other organic solvents. In some embodiments, the reaction is carried out at below room temperature, for example at about 0°C. In some embodiments, N,N-diisopropylethylamine is provided in molar excess relative to (15). In some embodiments, pyridine-sulfur trioxide is provided in molar excess relative to (15).
[0174] The intermediate 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (15) can be prepared by reacting 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate (14):
[0175]
[0176] Prepared by reaction with potassium carbonate, wherein Ac is acetyl. In some embodiments, the reaction is carried out in the presence of a solvent such as methanol, water, other polar solvents or mixtures thereof. In some embodiments, the reaction is carried out at below room temperature, such as at about 0°C. In some embodiments, potassium carbonate is provided in molar excess relative to (14).
[0177] The intermediate 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate (14) can be prepared by reacting 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (13):
[0178]
[0179] In some embodiments, the reaction is carried out in the presence of an organic solvent, wherein the organic solvent comprises toluene or other non-polar solvents. In some embodiments, the reaction is carried out at an elevated temperature, for example, at about 50°C to about 150°C or about 70°C to about 90°C or about 80°C to about 85°C. In some embodiments, acetic anhydride is provided in a molar excess relative to (13).
[0180] The intermediate 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (13) can be prepared by reacting 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (12):
[0181]
[0182] Prepared by reacting with urea hydrogen peroxide (UHP) in the presence of a catalyst. In some embodiments, the catalyst is a transition metal catalyst, such as methyltrioxorhenium (VII). In some embodiments, the catalyst is provided in a catalytic amount (e.g., <0.1 equivalent relative to (12). In some embodiments, the reaction is carried out in the presence of a solvent. In some embodiments, the solvent comprises methanol or other polar solvents. In some embodiments, the reaction is carried out at room temperature. In some embodiments, UHP is provided in an amount of about 1 to about 2 equivalents relative to (12) or in an amount of about 1.5 equivalents.
[0183] The intermediate 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (12) can be prepared by reacting 6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (11):
[0184]
[0185] With phosphorus oxychloride to prepare. In some embodiments, phosphorus oxychloride is provided in an amount of about 2-4 equivalents or about 3 equivalents relative to (11). In some embodiments, the reaction is carried out in the presence of an organic solvent, wherein the organic solvent comprises, for example, toluene. In some embodiments, the reaction is carried out at an elevated temperature, for example, at about 50°C to about 100°C or about 70°C to about 90°C or about 80°C to about 85°C.
[0186] The intermediate 6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (11) can be prepared by reacting 6,7-dihydro-5H-cyclopenta[b]pyridine (10):
[0187]
[0188] Prepared by reacting with urea hydrogen peroxide UHP in the presence of a catalyst. In some embodiments, the catalyst is a transition metal catalyst, such as methyltrioxorhenium (VII). In some embodiments, the catalyst is provided in a catalytic amount (e.g., <0.1 equivalent relative to (10). In some embodiments, the reaction is carried out at about room temperature. In some embodiments, UHP is provided in an amount of about 2-4 equivalents or about 3 equivalents relative to (10). In some embodiments, the reaction is carried out in the presence of a solvent, such as a solvent comprising methanol or other polar organic solvents. In some embodiments, the present invention relates to an intermediate compound selected from the following:
[0189]
[0190] Wherein TBS is tert-butyl(dimethyl)silyl.
[0191] In some embodiments, the present invention relates to an intermediate compound selected from the group consisting of:
[0192]
[0193] Wherein TBS is tert-butyl(dimethyl)silyl and Boc is tert-butyloxycarbonyl.
[0194] In some embodiments, the intermediate compound is
[0195] In some embodiments, the intermediate compound is
[0196] In some embodiments, the intermediate compound is Wherein TBS is tert-butyl(dimethyl)silyl.
[0197] In some embodiments, the intermediate compound is Wherein TBS is tert-butyl(dimethyl)silyl.
[0198] In some embodiments, the intermediate compound is Wherein TBS is tert-butyl(dimethyl)silyl.
[0199] In some embodiments, the intermediate compound is Wherein TBS is tert-butyl(dimethyl)silyl and Boc is tert-butyloxycarbonyl.
[0200] In some embodiments, the intermediate compound is Wherein TBS is tert-butyl(dimethyl)silyl and Boc is tert-butyloxycarbonyl.
[0201] In some embodiments, the intermediate compound is Wherein TBS is tert-butyl(dimethyl)silyl and Boc is tert-butyloxycarbonyl.
[0202] In some embodiments, the intermediate compound is Wherein TBS is tert-butyl(dimethyl)silyl and Boc is tert-butyloxycarbonyl.
[0203] In some embodiments, the present invention provides a method for preparing a phosphate salt of Compound 1, comprising:
[0204] reacting compound 10 with urea hydrogen peroxide and methyltrioxorhenium(VII) to form compound 11;
[0205] reacting compound 11 with phosphorus oxychloride to form compound 12;
[0206] reacting compound 12 with urea hydrogen peroxide and methyltrioxorhenium(VII) to form compound 13;
[0207] reacting compound 13 with acetic anhydride to form compound 14;
[0208] reacting compound 14 with potassium carbonate to form compound 15;
[0209] Reacting compound 15 with pyridine-sulfur trioxide in the presence of N,N-diisopropylethylamine to form compound 16;
[0210] Compound 16 is reacted with formic acid in the presence of RuCl(p-cymene) [(R,R)-Ts-DPEN] and triethylamine (TEA) to form compound 17;
[0211] Reacting compound 17 with tert-butyldimethylsilyl chloride and 1H-imidazole to form compound 18;
[0212] Compound 18 is combined with n-butyl lithium in the presence of 2,2,6,6-tetramethylpiperidine, followed by the addition of N,N-dimethylformamide (DMF) to form compound 19;
[0213] Reacting compound 19 with ammonia and iodine to form compound 20;
[0214] Reacting compound 20 with compound 9 or its hydrochloride in the presence of N,N-diisopropylethylamine (DIEA) to form compound 21;
[0215] reacting compound 21 with acetaldehyde oxime to form compound 22;
[0216] Compound 22 is mixed with tetra-N-butylammonium bromide (TBAB) in the presence of sodium hydroxide to form compound 23;
[0217] coupling compound 23 with compound 24 to form compound 25;
[0218] Reacting compound 25 with hydrogen chloride to form compound 1 dihydrochloride;
[0219] combining Compound 1 dihydrochloride with sodium carbonate to form Compound 1 free base; and
[0220] Compound 1 free base is combined with phosphoric acid to form Compound 1 phosphate salt.
[0221] In some embodiments, the present invention provides a method for preparing a phosphate salt of Compound 1, comprising:
[0222] Reacting compound 19 with ammonia and iodine to form compound 20;
[0223] Reacting compound 20 with compound 9 or its hydrochloride in the presence of N,N-diisopropylethylamine (DIEA) to form compound 21;
[0224] reacting compound 21 with acetaldehyde oxime to form compound 22;
[0225] Compound 22 is mixed with tetra-N-butylammonium bromide (TBAB) in the presence of sodium hydroxide to form compound 23;
[0226] coupling compound 23 with compound 24 to form compound 25;
[0227] Reacting compound 25 with hydrogen chloride to form compound 1 dihydrochloride;
[0228] combining Compound 1 dihydrochloride with sodium carbonate to form Compound 1 free base; and
[0229] Compound 1 free base is combined with phosphoric acid to form Compound 1 phosphate salt.
[0230] In some embodiments, the present invention provides a method for preparing compound 20, comprising:
[0231] reacting compound 10 with urea hydrogen peroxide and methyltrioxorhenium(VII) to form compound 11;
[0232] reacting compound 11 with phosphorus oxychloride to form compound 12;
[0233] reacting compound 12 with urea hydrogen peroxide and methyltrioxorhenium(VII) to form compound 13;
[0234] reacting compound 13 with acetic anhydride to form compound 14;
[0235] reacting compound 14 with potassium carbonate to form compound 15;
[0236] Reacting compound 15 with pyridine-sulfur trioxide in the presence of N,N-diisopropylethylamine to form compound 16;
[0237] Compound 16 is reacted with formic acid in the presence of RuCl(p-cymene) [(R,R)-Ts-DPEN] and triethylamine (TEA) to form compound 17;
[0238] Reacting compound 17 with tert-butyldimethylsilyl chloride and 1H-imidazole to form compound 18;
[0239] combining compound 18 with n-butyllithium in the presence of 2,2,6,6-tetramethylpiperidine followed by the addition of N,N-dimethylformamide (DMF) to form compound 19; and
[0240] Compound 19 is reacted with ammonia and iodine to form compound 20.
[0241] As used herein, the term "reaction" is used as known in the art and generally refers to bringing chemical reagents together in a manner that allows the chemical reagents to interact at the molecular level, thereby achieving a chemical or physical transformation. In some embodiments, the reaction involves at least two reagents. In some embodiments, the reaction steps of the synthesis process may involve one or more substances other than the reagents, such as solvents and / or catalysts. The reaction steps of the process described herein can be carried out under conditions suitable for preparing the identified product for a time suitable for preparing the identified product. In this article, the terms "combination" and "mixing" of reagents for chemical reactions can be used interchangeably with the term "reaction". The term "coupling" can also be considered interchangeable with "reaction", but can be used in conjunction with the reaction steps involving the connection of two organic fragments.
[0242] The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic methods, such as nuclear magnetic resonance spectroscopy (e.g. 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., ultraviolet-visible light) or mass spectrometry; or monitored by chromatography, such as high performance liquid chromatography (HPLC) or thin layer chromatography. The compound obtained by the reaction can be purified by any suitable method known in the art. For example, chromatography (medium pressure), HPLC or preparative thin layer chromatography on a suitable adsorbent (e.g., silica gel, alumina, etc.); distillation; sublimation, grinding or recrystallization. The purity of the compound is generally determined by physical methods, such as measuring the melting point (in the case of a solid), obtaining an NMR range or performing an HPLC separation. When the melting point is lowered, if the undesired signals in the NMR spectrum are reduced, or if the extraneous peaks in the HPLC depiction are removed, the compound can be said to be purified. In some embodiments, the compound is substantially purified.
[0243] The preparation of compounds can include the protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups can be easily determined by those skilled in the art. Protecting group chemistry can be found in, for example, Wuts and Greene, Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley & Sons: New York, 2006, which is incorporated herein by reference in its entirety.
[0244] The reactions of the processes described herein can be carried out at appropriate temperatures readily determined by the skilled artisan. The reaction temperature will depend, for example, on the melting and boiling points of the reagents and solvent (if present); the thermodynamics of the reaction (e.g., a vigorously exothermic reaction may require that it be carried out at a reduced temperature); and the kinetics of the reaction (e.g., a high activation barrier may require an elevated temperature). "Elevated temperature" refers to temperatures above room temperature (about 22° C.).
[0245] The reactions of the processes described herein can be carried out in suitable solvents, which can be easily selected by those skilled in the art of organic synthesis. Suitable solvents are substantially non-reactive with the starting material (reactant), intermediate or product at the temperature at which the reaction is carried out, i.e., at a temperature in the range of the solvent freezing temperature to the solvent boiling temperature. A given reaction can be carried out in a solvent or in a mixture of more than one solvent. Depending on the reaction step, a solvent suitable for a specific reaction step can be selected. Suitable solvents include water, alkanes (e.g., pentane, hexane, heptane, cyclohexane, etc., or mixtures thereof), aromatic solvents (e.g., benzene, toluene, xylene, etc.), alcohols (e.g., methanol, ethanol, isopropanol, etc.), ethers (e.g., dialkyl ethers, methyl tert-butyl ether (MTBE), tetrahydrofuran (THF), dioxane, etc.), esters (e.g., ethyl acetate, butyl acetate, etc.), halogenated hydrocarbon solvents (e.g., dichloromethane (DCM), chloroform, dichloroethane, tetrachloroethane), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetone, acetonitrile (ACN), hexamethylphosphoramide (HMPA), and N-methylpyrrolidone (NMP). Such solvents may be used in their wet or anhydrous form.
[0246] The resolution of the racemic mixture of a compound can be carried out by any of many methods known in the art. An exemplary method includes using "chiral resolution acid" to carry out fractional recrystallization, and the chiral resolution acid is an optically active salified organic acid. Suitable resolving agents for fractional recrystallization are, for example, optically active acids, such as tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or a variety of optically active camphorsulfonic acids in the form of D and L. The resolution of a racemic mixture can also be carried out by eluting on a column filled with an optically active resolution agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by those skilled in the art.
[0247] Preparation of Phosphate Crystalline Forms I-VI
[0248] Form I can be prepared, for example, by precipitating a solid form from a solution comprising N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate. In some embodiments, the solution comprises a solvent comprising 2-propanol. In other embodiments, the solution comprises a solvent comprising acetonitrile and / or ethanol. Precipitation can be carried out at any suitable temperature, such as about room temperature or at an elevated temperature. Precipitation can be carried out by any means of concentrating the solution, such as by evaporation, addition of an antisolvent, or cooling.
[0249] Form II can be prepared, for example, by precipitating a solid form from a solution of N-{(7R)-4-[(3R, 4R, 5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate in a solvent comprising dimethylformamide (DMF). Precipitation can be carried out by any means of concentrating the solution, for example, by evaporation, addition of an antisolvent, or cooling. In some embodiments, precipitation is carried out by evaporation under air at about room temperature (e.g., about 25°C).
[0250] Form III can be prepared by precipitating a solid form from a solution of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate in a solvent comprising dimethylformamide (DMF), wherein the precipitation can be carried out at an elevated temperature, for example, at about 30°C to about 70°C, at about 40°C to about 60°C, or at about 50°C.
[0251] Form IV can be prepared by precipitating a solid form from an aqueous solution of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate. In some embodiments, precipitation is performed by evaporation under air at elevated temperature, e.g., between about 30°C and about 70°C, between about 40°C and about 60°C, or between about 45°C and about 55°C.
[0252] Form V can be prepared by cooling an aqueous solution of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate and precipitating a solid form from the solution. In some embodiments, the aqueous solution is at a temperature of about 30°C to about 40°C or about 35°C prior to cooling. In some embodiments, the solution is cooled to about 4-5°C. In some embodiments, cooling is performed by quenching.
[0253] Form VI can be prepared by filtering a slurry of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate in water to obtain a filtrate, followed by cooling the filtrate (e.g., to below about 10°C or to about 4-5°C).
[0254] Synthesis of other salt forms
[0255] The dihydrochloride salt can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with hydrochloric acid. In some embodiments, the combination is carried out in the presence of a solvent, such as a solvent comprising 2-propanol and / or 2-propyl acetate. In some embodiments, hydrochloric acid is provided in a molar excess relative to the free base of Compound 1. In some embodiments, the molar ratio of the free base of Compound 1 to the hydrochloric acid is about 1:2 to about 1:2.5. In some embodiments, the ratio of the free base of Compound 1 to the hydrochloric acid is about 1:2.34.
[0256] The monohydrochloride salt can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with hydrochloric acid. In some embodiments, the combination is carried out in the presence of a solvent, such as a solvent comprising 2-propanol and / or 2-propyl acetate. In some embodiments, the molar ratio of Compound 1 free base to hydrochloric acid is about 1:1 to about 1:1.5. In some embodiments, the molar ratio of Compound 1 free base to hydrochloric acid is about 1:1.12.
[0257] Maleate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with maleic acid. In some embodiments, the combination is carried out in the presence of a solvent, such as a solvent comprising 2-propanol. In some embodiments, the molar ratio of Compound 1 free base to maleic acid is from about 1:1 to about 1:1.5. In some embodiments, the molar ratio of Compound 1 free base to maleic acid is about 1:1.21. In some embodiments, the method includes adding seed crystals to induce precipitation.
[0258] The adipate salt can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with adipic acid. In some embodiments, the combination is carried out in the presence of a solvent, such as a solvent comprising 2-propanol and / or heptane. In some embodiments, the molar ratio of Compound 1 free base to adipic acid is from about 1:2 to about 1:3. In some embodiments, the molar ratio of Compound 1 free base to adipic acid is about 1:2.49.
[0259] The hydrobromide salt can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with hydrobromic acid. In some embodiments, the combination is carried out in the presence of a solvent, such as a solvent comprising 2-propanol and / or water. In some embodiments, the molar ratio of Compound 1 free base to hydrobromic acid during the combination is from about 1:2 to about 1:3. In some embodiments, the molar ratio of Compound 1 free base to hydrobromic acid is about 1:2.4. In some embodiments, the hydrobromide salt is a dihydrobromide salt. In other embodiments, the hydrobromide salt is a monohydrobromide salt.
[0260] Mandelate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with (R)-(-)-mandelic acid. In some embodiments, the combination is carried out in the presence of a solvent, such as a solvent comprising 2-propanol. In some embodiments, the molar ratio of Compound 1 free base to (R)-(-)-mandelic acid during the combination is from about 1:1 to about 1:1.5. In some embodiments, the molar ratio of Compound 1 free base to (R)-(-)-mandelic acid is about 1:1.06.
[0261] Salicylate can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with salicylic acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the acid is provided in molar excess relative to the Compound 1 free base. In some embodiments, the molar ratio of Compound 1 free base to salicylic acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of Compound 1 free base to salicylic acid is about 1:1.16. In some embodiments, the combination is performed at about room temperature.
[0262] Benzoate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with benzoic acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the acid is provided in molar excess relative to the Compound 1 free base. In some embodiments, the molar ratio of Compound 1 free base to benzoic acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of Compound 1 free base to benzoic acid is about 1:1.16. In some embodiments, the combination is performed at about room temperature.
[0263] Benzenesulfonate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with benzenesulfonic acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the acid is provided in molar excess relative to the Compound 1 free base. In some embodiments, the molar ratio of Compound 1 free base to benzenesulfonic acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of Compound 1 free base to benzenesulfonic acid is about 1:1.1. In some embodiments, the combination is performed at about room temperature.
[0264] L-pyroglutamate can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with L-pyroglutamic acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the solvent comprises isopropanol and heptane. In some embodiments, the acid is provided in a molar excess relative to the free base of Compound 1. In some embodiments, the molar ratio of the free base of Compound 1 to L-pyroglutamic acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of the free base of Compound 1 to L-pyroglutamic acid is about 1:1.12. In some embodiments, the combination is performed at about room temperature.
[0265] Methanesulfonate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with methanesulfonic acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the solvent comprises isopropanol and ethanol. In some embodiments, the solvent comprises isopropanol, ethanol, and heptane. In some embodiments, the acid is provided in molar excess relative to the free base of Compound 1. In some embodiments, the molar ratio of the free base of Compound 1 to methanesulfonic acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of the free base of Compound 1 to methanesulfonic acid is about 1:1.1. In some embodiments, the combining is performed at about room temperature.
[0266] (1S)-(+)-10-camphorsulfonic acid salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with (1S)-(+)-10-camphorsulfonic acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the solvent comprises isopropanol and heptane. In some embodiments, the acid is provided in a molar excess relative to the Compound 1 free base. In some embodiments, the molar ratio of Compound 1 free base to (1S)-(+)-10-camphorsulfonic acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of Compound 1 free base to (1S)-(+)-10-camphorsulfonic acid is about 1:1.1. In some embodiments, the combining is performed at about room temperature.
[0267] Fumarate can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with fumaric acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the solvent comprises isopropanol and heptane. In some embodiments, the acid is provided in molar excess relative to the free base of Compound 1. In some embodiments, the molar ratio of the free base of Compound 1 to fumaric acid is about 1:1.16. In some embodiments, the combination is carried out at about room temperature.
[0268] Sulfate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with sulfuric acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the acid is provided in molar excess relative to the Compound 1 free base. In some embodiments, the molar ratio of Compound 1 free base to sulfuric acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of Compound 1 free base to sulfuric acid is about 1:1.1. In some embodiments, the combination is performed at about room temperature.
[0269] L-tartrate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with L-tartaric acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the solvent comprises isopropanol and heptane. In some embodiments, the acid is provided in molar excess relative to the Compound 1 free base. In some embodiments, the molar ratio of Compound 1 free base to L-tartaric acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of Compound 1 free base to L-tartaric acid is about 1:1.16. In some embodiments, the combination is performed at about room temperature.
[0270] D-tartrate salts can be prepared, for example, by combining N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) with D-tartaric acid, optionally in the presence of a solvent. In some embodiments, the solvent comprises isopropanol. In some embodiments, the solvent comprises isopropanol and heptane. In some embodiments, the acid is provided in molar excess relative to the Compound 1 free base. In some embodiments, the molar ratio of Compound 1 free base to D-tartaric acid is about 1:1 to about 1:1.5 or about 1:1 to about 1:1.2. In some embodiments, the molar ratio of Compound 1 free base to D-tartaric acid is about 1:1.16. In some embodiments, the combination is performed at about room temperature.
[0271] How to use
[0272] Compound 1 and salts described herein can inhibit the activity of one or more members of the Pim kinase family and are therefore useful for treating diseases and conditions associated with Pim kinase activity. For example, Compound 1 and its salts can inhibit one or more of Pim1, Pim2, and Pim3. Therefore, the present disclosure provides a method for treating a disease or condition associated with Pim kinase in an individual (e.g., a patient), by administering a therapeutically effective amount or dose of Compound 1 phosphate or any embodiment thereof or a pharmaceutical composition thereof to an individual in need of such treatment. The present disclosure also provides Compound 1 phosphate or any embodiment thereof or a pharmaceutical composition thereof for use in treating a disease or condition associated with Pim kinase. Also provided is the use of Compound 1 phosphate or any embodiment thereof or a pharmaceutical composition thereof for use in the manufacture of a medicament for treating a disease or condition associated with Pim kinase.
[0273] Diseases associated with Pim kinases may include any disease, disorder or condition directly or indirectly related to the expression or activity of Pim kinases, including overexpression and / or abnormal activity levels. Abnormal activity levels can be determined by comparing the activity levels in normal healthy tissues or cells with the activity levels in diseased cells. Diseases associated with Pim kinases may also include any disease, disorder or condition that can be prevented, improved, inhibited or cured by regulating the activity of Pim kinases. In some embodiments, the disease is characterized by abnormal activity or expression (e.g., overexpression) of one or more of Pim1, Pim2 and Pim3. In some embodiments, the disease is characterized by mutations in Pim1, Pim2 or Pim3. Diseases associated with Pim kinases may also refer to any disease, disorder or condition in which regulating the expression or activity of one or more Pim kinases is beneficial.
[0274] Diseases associated with Pim kinases that can be treated according to the present invention include cancers, particularly cancers in which Pim kinases are upregulated or oncogenes such as Myc or BCL2 are activated. Diseases associated with Pim kinases include solid tumors, such as prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head or neck cancer, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc. Diseases associated with Pim kinases also include blood cancers, such as lymphomas, leukemias, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, non-Hodgkin lymphoma (including relapsed non-Hodgkin lymphoma, refractory non-Hodgkin lymphoma and relapsed follicular non-Hodgkin lymphoma), Hodgkin lymphoma and multiple myeloma.
[0275] Pim kinase-related diseases that can be treated according to the present invention also include myeloproliferative disorders, such as polycythemia vera (PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML), etc. The myeloproliferative disorder can be myelofibrosis, such as primary myelofibrosis (PMF), post-polycythemia vera / essential thrombocythemia myelofibrosis (Post-PV / ET MF), post-essential thrombocythemia myelofibrosis (Post-ET MF) or post-polycythemia vera myelofibrosis (Post-PV MF).
[0276] Pim kinase-related diseases that can be treated according to the present invention also include immune disorders, such as autoimmune diseases. Immune disorders include multiple sclerosis, rheumatoid arthritis, allergies, food allergies, asthma, lupus, inflammatory bowel disease and ulcerative colitis.
[0277] Pim kinase-related diseases that can be treated according to the present invention also include atherosclerosis.
[0278] The salts of the invention may also be used to inhibit disease processes in which Pim kinases are involved, including angiogenesis and tumor metastasis.
[0279] Since Pim kinases are regulated by the JAK / STAT pathway, the salts of the present invention can be used to treat diseases in which regulating JAK / STAT signaling is beneficial. Therefore, other treatable diseases include Crohn's disease, irritable bowel syndrome, pancreatitis, diverticular disease, Graves' disease, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, myasthenia gravis, vasculitis, autoimmune thyroiditis, dermatitis, psoriasis, scleroderma, systemic sclerosis, vitiligo, graft-versus-host disease, Sjogren's syndrome, glomerulonephritis and diabetes (type I).
[0280] The terms "subject" or "patient" are used interchangeably and refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans.
[0281] The phrase "therapeutically effective amount" refers to that amount of an active compound or agent that elicits the biological or medical response in a tissue, system, animal, individual or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
[0282] The terms "treating" or "treatment" refer to one or more of the following: (1) inhibiting a disease; e.g., inhibiting a disease, condition or disorder in a subject experiencing or displaying pathology or symptoms of the disease, condition or disorder (i.e., preventing the pathology and / or symptoms from developing further); and (2) ameliorating a disease; e.g., ameliorating a disease, condition or disorder in a subject experiencing or displaying pathology or symptoms of the disease, condition or disorder (i.e., reversing the pathology and / or symptoms), e.g., reducing the severity of the disease.
[0283] In some embodiments, the salts of the invention are useful for preventing or reducing the risk of developing a disease; for example, preventing or reducing the risk of developing a disease, condition or disorder in an individual who is susceptible to the disease, condition or disorder but does not yet experience or display the pathology or symptoms of the disease.
[0284] Combination therapy
[0285] Cancer cell growth and survival may be affected by multiple signaling pathways. Therefore, it is desirable to combine different kinase inhibitors that exhibit different preferences for kinases that modulate activity to treat such conditions. Targeting more than one signaling pathway (or more than one biomolecule involved in a given signaling pathway) can reduce the likelihood of drug resistance emerging in a cell population, and / or reduce treatment toxicity.
[0286] Therefore, the Pim inhibitors of the present invention can be used in combination with one or more other kinase inhibitors for treating diseases such as cancer that are affected by multiple signaling pathways. For example, the combination can include one or more inhibitors of the following kinases for treating cancer: Akt1, Akt2, Akt3, TGF-βR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFαR, PDGFβR, CSFIR, KIT, FLK-II, KDR / FL K-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR / Flt2, Fl t4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Non-limiting examples of diseases that can be combined with the Pim inhibitors provided herein for the treatment of diseases such as cancer include FGFR inhibitors (FGFR1, FGFR2, FGFR3 or FGFR4), JAK inhibitors (JAK1 and / or JAK2, such as ruxolitinib, baricitinib or INCB39110), IDO inhibitors (such as epacadostat and NLG919), TDO inhibitors, PI3K-δ inhibitors, PI3K-γ inhibitors, CSF1R inhibitors, TAM receptor tyrosine kinases (Tyro-3, Axl and Mer), angiogenesis inhibitors, leukocyte factor receptor inhibitors and adenosine receptor antagonists or combinations thereof. In addition, the Pim inhibitors of the present invention can be combined with inhibitors of kinases associated with the PIK3 / Akt / mTOR signaling pathway (e.g., PI3K, Akt (including Akt1, Akt2 and Akt3) and mTOR kinase).
[0287] In some embodiments, the Pim inhibitors of the present invention can be combined with inhibitors that are selective for JAK1 and / or JAK2 (e.g., ruxolitinib, baricitinib, momelotinib, filgotinib, pacritinib, INCB039110, INCB052793, INCB054707, CYT387, ABT494, AZD1480, XL019, CEP-33779, AZ 960, TG101209, and gandotinib). In some embodiments, the Pim inhibitors of the invention can be used in combination with inhibitors selective for JAK1 (e.g., INCB039110, INCB052793, INCB054707, and ABT494), such as, for example, WO 2010 / 135650, WO 2011 / 028685, WO 2011 / 112662, WO 2012 / 068450, WO 2012 / 068440, WO 2012 / 177606, WO 2013 / 036611, WO 2013 / 026025, WO 2014 / 138168, WO 2013 / 173720, WO 2015 / 021153, WO 2014 / 071031, WO 2014 / 106706, WO2015 / 131031, WO 2015 / 168246 and WO 2015 / 184305. In some embodiments, the Pim inhibitors of the present invention can be combined with inhibitors selective for JAK2 (e.g., paritinib, AZD1480, XL019, CEP-33779, AZ 960, TG101209 and gandutinib).
[0288] In some embodiments, the Pim inhibitors of the invention can be used with inhibitors selective for PI3Kδ (e.g., idelalisib, INCB040093, INCB050465, and TGR 1202), such as, for example, WO 2011 / 0008487, WO 2011 / 075643, WO 2011 / 075630, WO 2011 / 163195, WO 2011 / 130342, WO 2012 / 087881, WO 2012 / 125629, WO 2012 / 135009, WO 2013 / 033569, WO 2013 / 151930, WO 2014 / 134426, WO 2015 / 191677, and WO Those inhibitor combinations disclosed in 2015 / 157257.
[0289] The Pim inhibitors of the present invention can be further used in combination with other methods for treating cancer, such as chemotherapy, radiotherapy, tumor-targeted therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine therapy (e.g., interferon, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccines, monoclonal antibodies, adoptive T cell transfer, oncolytic virus therapy and immunomodulatory small molecules, including thalidomide or JAK1 / 2 inhibitors. For example, the salt of the present invention can be administered in combination with one or more anticancer drugs, such as chemotherapeutic agents. Exemplary chemotherapeutic agents include any of the following: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, bleomycin, bortezomib, bortezomib, busulfan intravenous, busulfan oral oral), calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin-defucoxin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionatepropionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon α2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenylpropionatephenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate.
[0290] In some embodiments, the Pim inhibitors of the present invention can be combined with cytarabine.
[0291] Other anticancer agents include antibody therapeutics, such as trastuzumab (Herceptin), antibodies of costimulatory molecules (such as CTLA-4, 4-1BB, PD-1 and PD-L1) or antibodies of cytokines (IL-10, TGF-β, etc.). The Pim inhibitors presented herein can be further used in combination with one or more checkpoint inhibitors (such as inhibitors of immune checkpoint molecules). Exemplary immune checkpoint inhibitors include inhibitors for immune checkpoint molecules (such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK (such as JAK1 and / or JAK2), PI3Kδ, PI3Kγ, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1 and PD-L2). In some embodiments, immune checkpoint molecules are stimulatory checkpoint molecules selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, immune checkpoint molecules are inhibitory checkpoint molecules selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3 and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRβ inhibitors.
[0292] In some embodiments, immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as JAK1 and / or JAK2.
[0293] In some embodiments, immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD96.
[0294] In some embodiments, the inhibitor of an immune checkpoint molecule is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0295] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210 or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab.
[0296] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.
[0297] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab.
[0298] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525.
[0299] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK-4166. In some embodiments, the anti-GITR antibody is INCAGN01876.
[0300] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of OX40, such as an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562. In some embodiments, the OX40L fusion protein is MEDI6383. In some embodiments, the anti-OX40 antibody is INCAGN01949.
[0301] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of TIM3, such as an anti-TIM3 antibody.
[0302] In some embodiments, the Pim inhibitors of the present invention can be combined with TIGIT inhibitors.
[0303] The Pim inhibitors of the present invention can be used in combination with one or more other anticancer agents, including BET inhibitors (e.g., INCB054329, OTX015, and CPI-0610), LSD1 inhibitors (e.g., GSK2979552 and INCB059872), HDAC inhibitors (e.g., panobinostat, vorinostat, and entinostat), DNA methyltransferase inhibitors (e.g., azacitidine and decitabine), and other epigenetic regulators.
[0304] In some embodiments, the Pim inhibitors of the present invention can be combined with BET inhibitors. In some embodiments, the Pim inhibitors of the present invention can be combined with LSD1 inhibitors. In some embodiments, the Pim inhibitors of the present invention can be combined with HDAC inhibitors. In some embodiments, the Pim inhibitors of the present invention can be combined with DNA methyltransferase inhibitors.
[0305] The Pim inhibitors of the present invention can be used in combination with one or more agents for treating diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid or an immunomodulator. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL) and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (dexamethasone, DEX). In some embodiments, the immunomodulator is lenalidomide (LEN) or pomalidomide (pomalidomide, POM).
[0306] One or more anti-inflammatory agents, steroids, immunosuppressants, or therapeutic antibodies may also be combined with the salts of the invention.
[0307] When more than one agent is administered to a patient, they may be administered simultaneously, sequentially, or in combination (eg, more than two agents).
[0308] Formulation, Dosage Formulation and Administration
[0309] The salt of the present invention can be administered in the form of a pharmaceutical composition. Therefore, the present disclosure provides a composition comprising a salt of the present invention or any embodiment thereof and at least one pharmaceutically acceptable carrier. These compositions can be prepared by a well-known method in the pharmaceutical field, and can be administered by a variety of routes, depending on whether the indication is local or systemic treatment and the area to be treated. Administration can be local (including transdermal, transepidermal, ocular and transmucosal, including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or blowing into powder or aerosol, including by a nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular or injection or infusion; or intracranial (e.g., intrathecal) or intraventricular administration. Parenteral administration can be in the form of a single bolus dose, or can be, for example, by a continuous infusion pump. Pharmaceutical compositions and preparations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be needed or desirable.
[0310] The present invention also includes pharmaceutical compositions containing a combination of a salt of the present invention as an active ingredient and one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. When preparing the composition of the present invention, the active ingredient is usually mixed with an excipient, diluted by an excipient, or enclosed in such a carrier, in the form of, for example, a capsule, a sachet, paper or other container. When an excipient is used as a diluent, it can be a solid, semisolid or liquid substance, which is used as a vehicle, carrier or medium for the active ingredient. Therefore, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (in solid or in liquid media), ointments containing, for example, up to 10% by weight of active compounds, soft gelatin capsules and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
[0311] In preparing the formulation, the active compound can be milled before combining with the other ingredients to provide an appropriate particle size. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water-soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh.
[0312] The salts of the invention may be milled using known milling procedures, such as wet milling, to obtain a particle size suitable for forming tablets and other formulation types. Fine powder (nanoparticulate) formulations of the compounds of the invention may be prepared by processes known in the art, for example see WO 2002 / 000196.
[0313] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. The formulation may additionally include: lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl hydroxybenzoate and propyl hydroxybenzoate; and sweeteners and flavoring agents. The compositions of the present invention can be formulated using procedures known in the art to allow rapid, sustained or delayed release of the active ingredient after administration to the patient.
[0314] In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98% w / w microcrystalline cellulose and about 2% w / w silicon dioxide.
[0315] In some embodiments, the composition is a sustained release composition comprising at least one salt described herein and at least one pharmaceutically acceptable carrier. In some embodiments, the composition comprises a salt described herein and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein or a pharmaceutically acceptable salt thereof and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one salt described herein and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, microcrystalline cellulose is Avicel PH102 TM In some embodiments, lactose monohydrate is Fast-flo 316 TM In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208K4M (e.g., Methocel K4M Premier TM ) and / or hydroxypropyl methylcellulose 2208 K100LV (e.g. Methocel K00LV TM In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (e.g., PolyoxWSR 1105 TM ).
[0316] In some embodiments, a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.
[0317] The composition can be formulated in unit dosage form, each dose containing about 5 to about 1,000 mg (1 g), more typically about 100 mg to about 500 mg of active ingredient. In some embodiments, each dose contains about 10 mg of active ingredient. In some embodiments, each dose contains about 50 mg of active ingredient. In some embodiments, each dose contains about 25 mg of active ingredient. The term "unit dosage form" refers to a physically discrete unit suitable as a single dose for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect, combined with a suitable pharmaceutical excipient. Solid oral dosage forms include, for example, tablets, capsules, and pills.
[0318] The components used to formulate the pharmaceutical composition are of high purity and substantially free of potentially harmful contaminants (e.g., at least national food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or formulated in accordance with Good Manufacturing Practice standards as defined in applicable regulations of the US Food and Drug Administration. For example, suitable formulations may be sterile and / or substantially isotonic and / or in full compliance with the Good Manufacturing Practice regulations of the US Food and Drug Administration.
[0319] The active compound can be effective over a wide dosage range and is generally administered in a therapeutically effective amount. However, it will be appreciated that the amount of compound actually administered will generally be determined by a physician based on the relevant circumstances, including the condition to be treated, the selected route of administration, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, etc.
[0320] The therapeutic dose of the compounds of the present invention can be changed according to the specific use, the mode of administration of the compound, the health and condition of the patient, and the judgment of the attending physician, for example, for the treatment. The ratio or concentration of the compounds of the present invention in the pharmaceutical composition can be changed according to various factors, including dosage, chemical properties (such as hydrophobicity) and route of administration. For example, the compounds of the present invention can be provided in an aqueous physiological buffer solution containing about 0.1% w / v to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are about 1 μg per kilogram of body weight per day to about 1 g per kilogram of body weight per day. In some embodiments, the dosage range is about 0.01 mg per kilogram of body weight per day to about 100 mg per kilogram of body weight per day. The dosage may depend on variables such as the type and degree of progression of the disease or condition, the overall health status of the specific patient, the relative biological efficacy of the selected compound, the excipient formulation, and its route of administration. The effective dose can be extrapolated from a dose-response curve derived from an in vitro or animal model test system.
[0321] To prepare solid compositions, such as tablets, capsules, pills or other oral dosage forms, the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of the compound of the present invention. When these preformulation compositions are referred to as homogeneous, the active ingredient is generally evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms, such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the above type containing, for example, about 0.1 mg to about 1000 mg of the active ingredient of the present invention.
[0322] The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form that produces the advantage of prolonged action. For example, the tablet or pill may comprise an inner dose and an outer dose component, the latter being in the form of a coating on the former. The two components may be separated by an enteric coating layer that resists disintegration in the stomach and allows the inner component to enter the duodenum intact or to delay release. A variety of materials may be used for this enteric coating layer or coating, including a large amount of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.
[0323] Liquid forms in which the compounds and compositions of the invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions and emulsions flavored with edible oils (e.g., cottonseed oil, sesame oil, coconut oil, or peanut oil), as well as elixirs and similar pharmaceutical vehicles.
[0324] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the composition is administered by oral or nasal respiratory route for local or systemic effect. The composition may be atomized using an inert gas. The atomized solution may be breathed directly from the atomizing device or the atomizing device may be attached to a mask, curtain, or intermittent positive pressure breathing machine. Solutions, suspensions, or powder compositions may be administered orally or nasally from a device that delivers the preparation in an appropriate manner.
[0325] Topical preparations may contain one or more conventional carriers. In some embodiments, ointments may contain water and one or more selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white (petroleum gel) and the like. The carrier composition of the cream can be based on water and glycerol and one or more other components, such as glyceryl monostearate, PEG-glyceryl monostearate and cetyl stearyl alcohol. Gels can use isopropyl alcohol and water, suitably formulated with other components such as glycerol, hydroxyethyl cellulose, etc. In some embodiments, the topical preparation contains at least about 0.1wt%, at least about 0.25wt%, at least about 0.5wt%, at least about 1wt%, at least about 2wt% or at least about 5wt% of the compounds of the present invention. Topical preparations can be suitably packaged in, for example, 100g tubes, which are optionally associated with instructions for the treatment of selected indications, such as psoriasis or other skin conditions.
[0326] The amount of the compound or composition administered to the patient will vary depending on what is administered, the purpose of administration (e.g., prevention or treatment), the patient's state, the mode of administration, etc. In therapeutic applications, the composition can be administered to a patient already suffering from the disease in an amount sufficient to cure or at least partially prevent the symptoms of the disease and its complications. The effective dose will depend on the disease condition being treated, and will be judged by the clinician based on factors such as the severity of the disease, the patient's age, weight, and overall condition.
[0327] The composition administered to the patient may be in the form of the above-mentioned pharmaceutical composition. These compositions may be sterilized by conventional sterilization techniques, or may be aseptically filtered. The aqueous solution may be packaged for use as is, or lyophilized, and the lyophilized preparation may be combined with a sterile aqueous carrier prior to administration. The pH value of the compound formulation will generally be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It will be appreciated that the use of some of the above-mentioned excipients, carriers or stabilizers will form a pharmaceutically acceptable salt.
[0328] The therapeutic dose of the compounds of the present invention can be changed according to the specific use, the mode of administration of the compound, the health and condition of the patient, and the judgment of the attending physician, for example, for the treatment. The ratio or concentration of the compounds of the present invention in the pharmaceutical composition can be changed according to various factors, including dosage, chemical properties (such as hydrophobicity) and route of administration. For example, the compounds of the present invention can be provided in an aqueous physiological buffer solution containing about 0.1% w / v to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are about 1 μg per kilogram of body weight per day to about 1 g per kilogram of body weight per day. In some embodiments, the dosage range is about 0.01 mg per kilogram of body weight per day to about 100 mg per kilogram of body weight per day. The dosage may depend on variables such as the type and degree of progression of the disease or condition, the overall health status of the specific patient, the relative biological efficacy of the selected compound, the excipient formulation, and its route of administration. The effective dose can be extrapolated from a dose-response curve derived from an in vitro or animal model test system.
[0329] It will be appreciated that certain features of the invention which, for the sake of clarity, are described in the context of separate embodiments may also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiple dependent form). Conversely, various features of the invention which, for the sake of brevity, are described in the context of a single embodiment may also be provided separately or in any suitable subcombination.
[0330] The present invention will be described in more detail by specific examples. The following examples are provided only for illustrative purposes, and are not intended to limit the present invention in any way. Those skilled in the art will easily recognize multiple non-critical parameters, which can be changed or modified to obtain substantially the same result. Example
[0331] Example 1
[0332] Asymmetric Synthesis of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Phosphate
[0333]
[0334] Step 1. Synthesis of tert-butyl [(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-((7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-cyano-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-5-methylpiperidin-3-yl]carbamate (21)
[0335] To a stirred solution of (7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile (20) (see Example 5, 54.0 g, 173 mmol) (99.2% pure by HPLC) in anhydrous dimethyl sulfoxide (DMSO, 162 mL) in a 1-L RBF at room temperature was added tert-butyl ((3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate hydrochloride (9(HCl)) (see U.S. Patent Publication No. 2014 / 0200227, paragraph
[0769] , 70.0 g, 182.0 mmol, 1.05 equiv) and N,N-diisopropylethylamine (DIEA, 121 mL, 694 mmol, 4 equiv). The resulting reaction mixture was heated at 100° C. (oil bath) for 6 hours. When LCMS and HPLC showed the reaction was complete (≥98.5% conversion), the reaction mixture was cooled to room temperature with a water bath, diluted with water (400 mL), extracted twice with tert-butyl methyl ether (TBME) (700 mL and 400 mL). The organic layer was washed with brine (500 mL), dried over MgSO , filtered to remove the drying agent and concentrated in vacuo. The residue was purified by filtration chromatography (330 g silica gel column; eluted with 4 min 5% EtOAc / hexanes, then 6 min 25% EtOAc / hexanes) to afford the desired product, tert-butyl [(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-((7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-cyano-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-5-methylpiperidin-3-yl]carbamate (21) (100.6 g, 98.1% pure by HPLC, 92% yield) as an off-white solid. 1H NMR (400MHz, DMSO-d6) δ8.48(s,1H),6.75(d,J=9.4Hz,1H),5.01(dd,J=6.9,5.2Hz,1H),3.61(d,J=12.6Hz,1H),3. 52(d,J=12.4Hz,1H),3.48-3.36(m,1H),3.23(t,J=9.5Hz,1H),3.02(t,J=11.6Hz,2H),2.84(t,J=12.5Hz,1H),2.7 4(dt,J=15.2,7.6Hz,1H),2.32(td,J=12.9,8.0Hz,1H),1.82(ddd,J=13.3,8.1,4.3Hz,1H),1.75-1.60(m,1H),1.3 6(s,9H),0.94(d,J=6.5Hz,3H),0.87(s,9H),0.84(s,9H),0.13(s,3H),0.08(s,6H),0.06(s,3H)ppm; LCMS(EI)m / z 617.4(C 32 H 57 N4O4Si2,(M+H) + ).
[0336] Step 2. Synthesis of tert-butyl ((3R,4R,5S)-1-((7R)-3-(aminocarbonyl)-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate (22)
[0337] To a stirred solution of tert-butyl [(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-((7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-cyano-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-5-methylpiperidin-3-yl]carbamate (21) (65.0 g, 105 mmol) in ethanol (195 mL) in a 2-L RBF at room temperature were added [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)2Cl2 complex with dichloromethane (1:1); 1.721 g, 2.107 mmol, 0.02 equiv), acetaldehyde oxime (32.8 mL, 527 mmol, 5.0 equiv) and water (65 mL). The resulting reaction mixture was degassed and backfilled with N2 three times, then heated to reflux (oil bath; temperature at about 90°C) for 6 hours. An additional amount of acetaldehyde oxime (32.8 mL, 527 mmol, 5.0 equiv.) was added. The reaction mixture was then reheated to reflux (oil bath; temperature at about 90°C) for 16 hours. When LCMS and HPLC showed that the reaction was complete (≥96.5% conversion), the hot reaction mixture was treated with water (390 mL) and then gradually cooled to room temperature. The resulting slurry was stirred at room temperature for another 30 minutes and then collected by filtration. The wet cake was washed with water (3×100 mL) and then re-slurried in a mixture of acetonitrile and water (400 mL; acetonitrile: water: 1:3 by volume). The solid was collected by filtration, washed with water (3 x 100 mL), and dried under house vacuum at room temperature overnight to afford the desired product, tert-butyl ((3R,4R,5S)-1-((7R)-3-(aminocarbonyl)-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate (22) as a light brown powder which was used in the subsequent reaction without further purification. 1H NMR (400MHz, DMSO-d6) δ8.16(s,1H),7.84(s,1H),7.46(s,1H),6.66(d,J=9.6Hz,1H),5.01(dd,J=6.8,4. 7Hz,1H),3.48-3.36(m,1H),3.23-3.07(m,3H),3.01-2.88(m,1H),2.82(t,J=11.7Hz,1H),2.74-2.58(m, 2H),2.35(dt,J=12.3,6.0Hz,1H),1.84(dt,J=13.1,6.6Hz,1H),1.72-1.56(m,1H),1.35(s,9H),0.90(d, J=6.6Hz,3H),0.87(s,9H),0.84(s,9H),0.14(s,3H),0.08(s,3H),0.07(s,3H),0.06(s,3H); LCMS(EI)m / z 635.4(C 32 H 59 N4O5Si2,(M+H) + ).
[0338] Step 3. Synthesis of tert-butyl ((3R,4R,5S)-1-(3-amino-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate (23)
[0339] To a stirred solution of tert-butyl ((3R,4R,5S)-1-((7R)-3-(aminocarbonyl)-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate (22) (66.9 g, 105 mmol) in tetrahydrofuran (THF, 470.0 mL) at 0 °C in a 2-L 3-neck RBF was added tetra-N-butylammonium bromide (34.30 g, 105.4 mmol, 1.0 equiv) and 3.0 M aqueous sodium hydroxide solution (158.0 mL, 474.1 mmol, 4.5 equiv). Then 1,3-dibromo-5,5-dimethylhydantoin (21.52 g, 73.75 mmol, 0.7 eq) was added portionwise over 44 minutes to control the reaction temperature at 5 to 10 ° C. The resulting dark brown solution was stirred for another 20 minutes at 5 to 10 ° C. When LCMS showed that the reaction was complete, the reaction mixture was diluted with MTBE (100 mL), quenched with 10% Na2S2O3 aqueous solution (300 mL) and water (200 mL). The two phases were separated, and the aqueous phase was extracted with MTBE (2×600 mL). The combined organic layer was washed with water (500 mL), dried over MgSO4, filtered to remove the desiccant and concentrated in vacuo to give the crude product (63.7 g) as a brown foam solid. The crude product was purified by filtration chromatography (330 g silica gel column; eluting with 20% EtOAc / hexanes for 6 minutes, then 45% EtOAc / hexanes for 8 minutes) followed by recrystallization from heptane (180 mL) to afford the desired product, tert-butyl ((3R,4R,5S)-1-(3-amino-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate (23) (46.2 g, 100.0% pure by HPLC, 72% yield over two steps) as an off-white solid. 1H NMR (400MHz, DMSO-d6) δ7.80(s,1H),6.61(d,J=9.7Hz,1H),4.88(dd,J=6.8,3.6Hz,1H),4.81(s, 2H),3.52(td,J=9.8,4.6Hz,1H),3.14(t,J=9.5Hz,1H),3.04-2.84(m,3H),2.85-2.68(m,2H),2. 48-2.42(m,1H),2.23(dq,J=13.2,6.9Hz,1H),1.79(dq,J=12.6,4.4Hz,2H),1.35(s,9H),0.89(d ,J=6.6Hz,3H),0.85(s,18H),0.10(s,3H),0.08(s,3H),0.06(s,3H),-0.00(s,3H); LCMS(EI)m / z 607.4(C 31 H 59 N4O4Si2,(M+H) + ).
[0340] Step 4. Synthesis of tert-butyl {(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-[(7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-({[6-(2,6-difluorophenyl)-5-fluoropyridin-2-yl]carbonyl}amino)-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl]-5-methylpiperidin-3-yl}carbamate (25)
[0341] To a stirred mixture of tert-butyl ((3R,4R,5S)-1-(3-amino-7-{[tert-butyl(dimethyl)silyl]oxy}-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-methylpiperidin-3-yl)carbamate (23) (100.0 g, 164.8 mmol) and 6-(2,6-difluoro- A solution of 1-(4-(phenyl)-5-fluoropicolinic acid (24) (see U.S. Patent Publication No. 2014 / 0200227, paragraph
[0625] , 50.05 g, 197.7 mmol, 1.2 equiv) in anhydrous N,N-dimethylformamide (DMF, 320.0 mL) was added with N,N-diisopropylethylamine (DIEA, 137.8 mL, 790.8 mmol, 4.8 equiv). After stirring at room temperature for 10 minutes, the reaction mixture was treated with N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU, 150.3 g, 395.4 mmol, 2.4 equiv) portionwise to control the temperature between 15°C and 30°C. The reaction mixture was then stirred at room temperature for 30 minutes. When LCMS and HPLC showed that the reaction was complete, the reaction mixture was filtered into water (1300mL) under stirring. The resulting slurry was stirred for another 30 minutes at room temperature. The solid was collected by filtration and washed with a mixture of 50% acetonitrile and water (50 volume %; 2×200mL). The wet solid was then treated with acetonitrile (420mL) and the resulting slurry was heated at 70°C until a clear solution was produced. At 70°C, water (320mL) was slowly added to the solution, and the resulting mixture was gradually cooled to room temperature and stirred at room temperature for 30 minutes. The solid was collected by filtration, washed with a mixture of acetonitrile and water (50% by volume; 320 mL) and dried in a vacuum oven at 50 °C overnight to give the desired product, tert-butyl {(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-[(7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-({[6-(2,6-difluorophenyl)-5-fluoropyridin-2-yl]carbonyl}amino)-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl]-5-methylpiperidin-3-yl}carbamate (25) (131.8 g, 99.7% pure by HPLC, 95% yield) as a white powder. 1H NMR (400MHz, DMSO-d6) δ10.39(s,1H),8.95(s,1H),8.36(dd,J=8.7,4.0Hz,1H),8.19(t,J=8.9Hz,1H),7.67-7.55(m,1H),7.2 7(t,J=8.5Hz,3H),6.46(d,J=9.6Hz,1H),5.00(dd,J=6.8,4.2Hz,1H),3.40(dd,J=9.3,5.9Hz,1H),3.05(t,J=9.4Hz,2H),2.93 (t,J=10.8Hz,4H),2.82(dt,J=15.8,8.1Hz,1H),2.56(t,J=11.7Hz,1H),2.40-2.26(m,1H),1.92-1.79(m,1H),1.54(s,0H),1. 32(s,9H),0.87(s,11H),0.84(s,9H),0.71(d,J=6.5Hz,4H),0.14(s,4H),0.07(s,3H),0.04(s,4H),0.01(s,3H); LCMS(EI)m / z 842.4(C 43 H 63 F3N5O5Si2,(M+H) + ).
[0342] Step 5. Synthesis of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide dihydrochloride (Compound 1 dihydrochloride)
[0343] To a slurry of tert-butyl {(3R,4R,5S)-4-{[tert-butyl(dimethyl)silyl]oxy}-1-[(7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-({[6-(2,6-difluorophenyl)-5-fluoropyridin-2-yl]carbonyl}amino)-6,7-dihydro-5H-cyclopenta[b]pyridin-4-yl]-5-methylpiperidin-3-yl}carbamate (25) (3121.0 g, 3706.0 mmol) in methanol (19.5 L) was added 4.0 M hydrogen chloride in 1,4-dioxane (13.9 L, 55600 mmol, 15.0 equiv) at room temperature. The internal temperature rose from 17.3° C. to 36.8° C. during the addition of the HCl in 1,4-dioxane solution. The resulting light yellow solution was stirred at room temperature for 22 hours and solids (2HCl salt) began to precipitate from the solution within 2 hours. When LCMS and HPLC indicated the reaction was complete, the solids were collected by filtration, washed with heptane (5 L), and dried on the filter under vacuum overnight to give the desired product, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide dihydrochloride (Compound 1 dihydrochloride) (2150.0 g, 99.1% pure by HPLC, 98% yield) as a white powder. 1 HNMR (400MHz, DMSO-d6) δ10.57(s,1H),8.57(s,3H),8.36(dd,J=8.7,4.1Hz,1H),8.22(t,J=8.8Hz,1H),7.69(d dd,J=15.1,8.5,6.7Hz,1H),7.34(t,J=8.1Hz,2H),5.27(t,J=7.0Hz,1H),4.02(d,J=11.1Hz,1H),3.44(d,J=11 .3Hz,1H),3.29(t,J=12.2Hz,1H),3.13(q,J=8.5,7.4Hz,2H),3.09-2.97(m,2H),2.77(t,J=12.3Hz,1H),2.56- 2.50(m,1H),1.95(dq,J=14.9,7.7,7.2Hz,1H),1.66-1.50(m,1H),0.70(d,J=6.5Hz,3H); LCMS(EI)m / z514.2(C 26 H 27 F3N5O3,(M+H) + ).
[0344] Step 6. Synthesis of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base)
[0345] 200L glass reactor is equipped with overhead stirrer, condenser, thermocouple, addition funnel and nitrogen inlet and this equipment is purged with nitrogen.Sodium carbonate (18,264g) and drinking water (86.2L) are fed into the reactor and stirred for about 50 minutes until a solution is obtained.Dichloromethane (107.8L) is fed into the reactor.N-{(7R)-4-[(3R, 4R, 5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopentadiene [b] pyridine-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide dihydrochloride (Compound 1 dihydrochloride) (4300g) is fed into the reactor through about 27 minutes, while maintaining the temperature at about 27 ° C, and stirring the reaction mixture at about 23 ° C for about 22 hours, until a clear solution is obtained. The phases were separated and the aqueous phase was extracted with dichloromethane (26.9 L). The combined organic phases were washed twice with drinking water (26.9 L each time) and concentrated under reduced pressure at about 54 °C to give the desired product, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base, 3838 g) as a light yellow solid, which was used directly in the subsequent reaction without further purification. LCMS (EI) m / z 514.2 (C 26 H 27 F3N5O3,(M+H) + ).
[0346] Step 7. Synthesis of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphoric acid (Compound 1 phosphate salt)
[0347] A 100 L glass reactor was equipped with an overhead stirrer, condenser, thermocouple, addition funnel, and nitrogen inlet and the apparatus was purged with nitrogen. Phosphoric acid solution was prepared separately by thoroughly mixing an aqueous solution of 85% H3PO4 (980 g) with 2-propanol (IPA, 5.7 L) at room temperature. The phosphoric acid solution was polish filtered through an in-line filter. Methanol (19.0 L), USP purified water (1.9 L), and 2-propanol were polish filtered through in-line filters, respectively. Filtered methanol (19.0 L), N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide (Compound 1 free base) (3800 g), filtered USP purified water (1.9 L), and filtered 2-propanol (15.2 L) were fed sequentially to the reactor. The reaction mixture was heated to about 56° C. Filtered phosphoric acid solution (5.8 L) was fed to the reactor over about 45 minutes while maintaining the temperature at about 59° C. The vessel was rinsed into the reaction mixture with filtered 2-propanol (5.8 L) while maintaining the temperature at about 62° C. Filtered 2-propanol (15.2 L) was fed while maintaining the temperature at about 58° C., and the reaction mixture was stirred at about 57° C. for about 1.5 hours. The reaction mixture was cooled to about 26° C. and stirred at about 17° C. for about 3.5 hours. The reaction mixture was filtered and the filter cake was washed sequentially with filtered 2-propanol (22.8 L) and filtered heptane (prepared individually by polish filtering 22.8 L of heptane through an in-line filter). The product was dried on the filter and then dried under reduced pressure at 20-54 °C to give the desired product, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate (Compound 1 phosphate) (3952 g, >99.0% pure by HPLC, 87.3% yield) as a white to off-white crystalline solid.
[0348] 1H NMR (400MHz, DMSO-d6) δ10.43(s,1H),9.25(s,1H),8.38(dd,J=8.7,4.1Hz,1H),8.20(t,J=8.8Hz,1H ),7.66(ddd,J=15.2,8.4,6.7Hz,1H),7.32(t,J=8.6Hz,2H),7.19(s,2H),4.82(dd,J=6.9,4.5Hz,1H) ,3.22(d,J=6.9Hz,1H),3.18-2.99(m,3H),2.87(d,J=8.0Hz,2H),2.79-2.67(m,1H),2.59(t,J=11.5H z,1H),2.27(dt,J=13.5,6.6Hz,1H),1.92-1.74(m,1H),1.58–1.39(m,1H),0.70(d,J=6.5Hz,3H)ppm; 13 C NMR(100MHz,DMSO-d6)δ163.1,160.5,159.5(dd,J CF =249.4,6.6Hz),159.0(d,J CF =261.8Hz),146.0(d,J CF =4.2),144.6,136.1(J CF =18.6),140.8,132.8(t,J CF =10.6Hz),130.6,128.5,126.2(d,J CF =20.5),125.4(d,J CF =6.4),112.4(d,J CF =20.8Hz),110.7(td,J CF =19.5,3.6Hz),74.9,72.8,55.7,54.0,52.4,37.7,33.1,26.9,14.4ppm; 19 F NMR(376MHz, DMSO-d6)δ-117.26(m,1F),-113.77(m,2F)ppm; LCMS(EI)m / z 514.2(C 26 H 27 F3N5O3,(M+H) + ).
[0349] The quantitative elemental microscopic analysis results of carbon, hydrogen and nitrogen on the phosphate of compound 1 are consistent with the proposed empirical formula (C 26 H 29 F3N5O7P). 26 H29 Anal. Calc. for F3N5O7P: C, 51.07; H, 4.78; N, 11.45. Found: C, 51.16; H, 4.70; N, 11.56.
[0350] Example 2
[0351] X-ray powder diffraction (XRPD) of Compound 1 Phosphate Form I
[0352] Crystalline N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate Form I (see Example 1, Step 7) was characterized by XRPD. X-ray powder diffraction (XRPD) patterns were obtained on a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was as follows: (1) X-ray radiation was from copper, at Next, K β filter; (2) X-ray power at 30 KV, 15 mA; and (3) sample powder dispersed on a zero-background sample holder. The general measurement conditions of XRPD are as follows: start angle 3°; stop angle 45°; sampling at 0.02°; and scanning speed 2° / min. Figure 1 The XRPD pattern is shown in and the XRPD data are provided in Table 1.
[0353] Table 1. XRPD data of Form I
[0354]
[0355]
[0356] Example 3
[0357] Differential Scanning Calorimetry (DSC) of Compound 1 Phosphate (Form I)
[0358] The crystalline solid N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate (see Example 1, Step 7) was characterized by DSC. DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler. The DSC instrument conditions were as follows: 30°C-350°C at 10°C / min; Tzero aluminum sample pan and cover; and nitrogen flow rate was 50 mL / min. Figure 2 The DSC thermogram is shown in . The DSC thermogram revealed a major endothermic event (believed to be melting / decomposition) with an onset temperature of 238.8° C. and a peak temperature at 247.1° C. and a minor endothermic event with an onset temperature of 193.1° C. and a peak temperature at 198.4° C. Multiple Form I batches were characterized by DSC, each having a thermogram with a major endothermic peak occurring in the range of 249.7° C. to 254.7° C.
[0359] Example 4
[0360] Thermogravimetric analysis (TGA) of Compound 1 phosphate (Form I)
[0361] The crystalline solid N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate (see Example 1, Step 7) was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions for the TGA were as follows: ramping from 20°C to 600°C at 20°C / min; nitrogen purge, gas flow was 40 mL / min, followed by purge gas flow balance; sample purge gas flow was 60 mL / min; platinum sample pan. Figure 3 The TGA thermogram is shown in Figure 1. A weight loss of about 2% below 200°C was observed and is believed to be related to the loss of water and residual solvent. Karl-Fischer analysis was performed on multiple synthetic batches of Form I, and each experiment revealed that the water content was in the range of 1.40%-1.50%, indicating that Form I may be a hydrate, such as a hemihydrate.
[0362] Example 5
[0363] Asymmetric Synthesis of (7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile (20)
[0364]
[0365] Step 1. 6,7-Dihydro-5H-cyclopenta[b]pyridine 1-oxide (11)
[0366]
[0367] To a mixture of 6,7-dihydro-5H-cyclopenta[b]pyridine (10) (10.0 g, 83.9 mmol) in methanol (50 mL) was added urea hydrogen peroxide adduct (UHP, 24 g, 250 mmol, 3.0 equiv) and methyltrioxorhenium (VII) (80 mg, 0.3 mmol, 0.0036 equiv) at room temperature. The resulting mixture was stirred at room temperature overnight and then concentrated under reduced pressure to remove methanol. After no more distillate was observed, dichloromethane (100 mL) was added and concentration continued. The resulting residue was treated with dichloromethane (100 mL) and stirred at room temperature for 10 minutes. The solid was filtered and extracted 3 times (3×50 mL) with dichloromethane. The combined filtrate was dried over anhydrous sodium sulfate (Na2SO4) and sodium bisulfite (NaHSO3) and then filtered through a silica gel pad (SiO2). The pad was rinsed 3 times with 10% MeOH in CH2CH2 (100 mL). The combined filtrates were concentrated to give the desired product, 6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (11, 11.5 g, 99% yield) as an off-white solid, which was used in subsequent reactions without further purification. For 11: 1 HNMR(300MHz, CDCl3)δ8.05(d,J=6.0Hz,1H),7.08(m,2H),3.15.(t,J=6.0Hz,2H),3.00.(t,J=6.0Hz,2H),2.16(m,2H)ppm; LCMS(EI)m / z 136(C8H9NO,(M+H) + ).
[0368] Step 2. 4-Chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (12)
[0369]
[0370] 6,7-Dihydro-5H-cyclopenta[b]pyridine 1-oxide (11, 12.0 g, 84.3 mmol) was slowly added to phosphorus oxychloride (POCl3, 24 mL, 250 mmol, 3.0 equiv) and toluene (48 mL) at 80°C-85°C (internal temperature) over 2 hours, wherein each portion was about 0.2 g. After the addition was completed, the reaction mixture was stirred at 80°C-85°C (internal temperature) for 3 hours. Excess POCl3 and toluene were removed at 60°C under reduced pressure. The resulting residue was then poured into a cooled mixture of ice (50 g) and saturated aqueous sodium carbonate solution (Na2CO3, 50 mL). The pH of the mixture was adjusted to 8 using 25% aqueous sodium hydroxide solution (NaOH, about 30 mL). The mixture was then extracted with dichloromethane (3×100 mL). The combined organic extracts were dried over anhydrous Na2SO4 and filtered through a silica gel pad (SiO2, 36 g) and charcoal (6 g, on top of silica gel). The pad was rinsed with ethyl acetate (4×100 mL) until no desired product was produced from the silica gel pad. The combined filtrate was then concentrated under reduced pressure to give the crude desired product (12, 10.93 g). 3-Chlorobenzoic acid (11 g, 73 mmol) was added to a mixture of crude 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (12, 10.7 g, 69.6 mmol) in THF (50 mL) at room temperature. The mixture was then stirred at room temperature until 3-chlorobenzoic acid dissolved. The mixture was concentrated under reduced pressure to produce a crude salt in the form of a solid, which was treated with hexane (32 mL). The resulting suspension was stirred at room temperature for 10 minutes. The solid was collected by filtration and washed with hexane (2×32 mL). More solids were collected from the filtrate. The combined wet solids (about 18 g) were dissolved in dichloromethane (100 mL) and treated with saturated aqueous Na2CO3 (2×20 mL). The aqueous layer was back extracted with dichloromethane (50 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated to give the purified desired product, 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (12, 7.1 g) as a dark oil. About 12: 1 HNMR(300MHz, CDCl3)δ8.20(d,J=3.0Hz,1H),7.02(d,J=3.0Hz,1H),3.06.(t,J=6.0H z,2H),2.98.(t,J=6.0Hz,2H),2.12(m,2H)ppm; LCMS(EI)m / z154 / 156(C8H8ClN,(M+H) + ).
[0371] Step 3. 4-Chloro-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (13)
[0372]
[0373] To a mixture of 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (12, 100.0 g, 618.4 mmol) in methanol (500 mL) was added urea hydrogen peroxide adduct (UHP, 1.5 eq., 87.3 g, 928 mmol, 1.5 eq.) and methyltrioxorhenium (VII) (925 mg, 3.71 mmol, 0.006 eq.) at room temperature. The resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure to remove methanol. Dichloromethane (500 mL) was added and the concentration was continued. The resulting residue was treated with dichloromethane (500 mL) and the resulting mixture was stirred for 30 minutes. The solid was filtered and extracted with dichloromethane (4×500 mL). The combined filtrate was dried over anhydrous sodium sulfate (Na2SO4) and sodium bisulfite (NaHSO3). The mixture was then filtered through a pad of silica gel (SiO2, 180 g) and activated carbon (10 g). The pad was rinsed three times with 10% MeOH in CH2CH2 (500 mL). The combined filtrates were concentrated under reduced pressure to give the desired product, 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (13, 104 g) as an off-white solid. About 13: 1 HNMR(300MHz, DMSO-d6)δ8.04(d,J=6.0Hz,1H),7.34(d,J=6.0Hz,1H),2.98.(m,4H),2.08(m,2H)ppm; LCMS(EI)m / z 170 / 172(C8H8ClNO,(M+H) + ).
[0374] Step 4. 4-Chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate (14)
[0375]
[0376] 4-Chloro-6,7-dihydro-5H-cyclopenta[b]pyridine 1-oxide (13) (65.0 g, 340 mmol) was added to a mixture of acetic anhydride (Ac2O, 98 mL, 1000 mmol) and toluene (325 mL) in portions (6 g each) over 1 hour at 80°C-85°C. After the addition was complete, the resulting mixture was stirred at 80°C-85°C for 3 hours. When LCMS and / or HPLC indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure to remove acetic anhydride and toluene. The resulting crude desired product, acetic acid 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-7-yl ester (14), was used directly in subsequent reactions without further purification. About 14:1 HNMR(300MHz,DMSO-d6)δ8.38(d,J=6.0Hz,1H),7.21(d,J=6.0Hz,1H),6.14.(m,1H),3.0 8(m,1H),2.93(m,1H),2.64(m,1H),2.10(s,3H),2.07(m,1H)ppm; LCMS(EI)m / z212 / 214(C 10 H 10 ClNO2,(M+H) + ).
[0377] Step 5. 4-Chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (15)
[0378]
[0379] To a mixture of acetic acid 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl ester (14, 73 g, 340 mmol, nested from the last step) in MeOH (130 mL) and water (130 mL) was added potassium carbonate (K2CO3, 130 g, 920 mmol) at 0°C. The resulting mixture was gradually warmed to room temperature and stirred at room temperature for 4 hours. The reaction mixture was then concentrated under reduced pressure to remove methanol. The precipitated solid was collected by filtration, washed with water (3×100 mL), and dried to give a first portion of crude product (15). The aqueous layer was extracted with DCM (3×300 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated to give a second portion of crude product (15). The crude desired product, 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (15, 61.9 g, 93% yield over 2 steps) was obtained as a dark brown oil from two portions and was used directly in the subsequent reaction without further purification. 1 HNMR(300MHz,DMSO-d6)δ8.34(d,J=3.0Hz,1H),7.18(d,J=3.0Hz,1H),5.26.(t,J =3.0Hz,1H),3.08(m,1H),2.86(m,1H),2.60(m,1H),2.09(m,1H)ppm; LCMS(EI)m / z 170 / 172(C8H8ClNO,(M+H) + ).
[0380] Step 6. 4-Chloro-5H-cyclopenta[b]pyridin-7(6H)-one (16)
[0381]
[0382] To a solution of 4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-7-ol (15, 110.3 g, 650.32 mmol) in dichloromethane (800 mL) was added N,N-diisopropylethylamine (339.5 g, 2627.0 mmol) at room temperature. After the mixture was cooled to 0 ° C, dimethyl sulfoxide (DMSO, 800 g) containing pyridine-sulfur trioxide (1: 1) (200.0 g, 1256.6 mmol) was added dropwise over 35 minutes and the resulting mixture was stirred at 0 ° C for 1 hour. The reaction progress was monitored by HPLC and about 30% of the starting material 15 remained. Additional amounts of pyridine-sulfur trioxide (1: 1) (138 g, 866.8 mmol) and N,N-diisopropylethylamine (79.8 g, 617 mmol) were added, and the reaction mixture was stirred for another 2 hours under an ice bath. Water (1000mL) is added to the reaction mixture, and the resulting mixture is concentrated under reduced pressure to remove dichloromethane. The resulting residue is carefully poured into a saturated NaHCO aqueous solution (2000mL). The solid is collected by filtration, washed with water (2×200mL), and dried to obtain the first part of the thick desired product (16). The aqueous filtrate is extracted with dichloromethane (2×200mL). The combined organic extracts are dried over anhydrous Na2SO4, filtered and concentrated to obtain the second part of the thick desired product (16). The combined thick desired product is purified by silica gel flash chromatography (SiO2, eluted with 0 to 50% ethyl acetate / hexane) to obtain the desired product in a yellow to brown oily state, 4-chloro-5H-cyclopentadiene [b] pyridine-7 (6H) -one (16, 87g, 80% yield), which is left to solidify in a vacuum. About 16: 1 HNMR(300MHz,DMSO-d6)δ8.68(d,J=6.0Hz,1H),7.48(d,J=6.0Hz,1H),3.18(m,2H),2.81(m,2H)ppm; LCMS(EI)m / z168 / 170(C8H6ClNO,(M+H) + ).
[0383] Step 7. (R)-4-Chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol (17)
[0384]
[0385] To a solution of 4-chloro-5H-cyclopenta[b]pyridine-7(6H)-one (16, 138.0 g, 823.4 mmol) and triethylamine (TEA, 573.8 mL, 4117 mmol) in dichloromethane (1100 mL) was added RuCl(p-cymene)[(R,R)-Ts-DPEN](1.31 g, 2.06 mmol) at room temperature. The resulting mixture was degassed, cooled to 5°C-10°C, and stirred at 5°C-10°C under nitrogen. Formic acid (155.3 mL, 4117 mmol) was then slowly added to the reaction mixture at 7°C-14°C (internal temperature). After addition, the reaction mixture was gradually warmed to room temperature and stirred at room temperature for 22 hours. When LC / MS and HPLC showed that the reaction was complete, the reaction mixture was quenched with saturated aqueous sodium bicarbonate solution (NaHCO3) (1000 mL) and water (1500 mL). The two layers were separated and the aqueous layer was extracted with dichloromethane (3×500 mL). The organic layers were combined, dried over anhydrous Na2SO4, filtered and concentrated to give the crude desired product (R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-7-ol (17, assumed yield 100%) as a yellow to brown oil, which was used directly in the subsequent reaction without further purification. About 17: 1 HNMR (300MHz, DMSO-d6) δ8.33(d,J=6.0Hz,1H),7.19(d,J=6.0Hz,1H),5.27(m,1H),3.08(m,1H),2.86(m,1H),2.57(m,1H),2.10(m,1H)ppm; LCMS(EI)m / z 170 / 172(C8H8ClNO,(M+H) + ).
[0386] Step 8. (R)-7-(tert-Butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (18)
[0387]
[0388] To a stirred solution of (R)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-7-ol (17, 172.25 g, 1015.6 mmol) in anhydrous dichloromethane (2500 mL) was added tert-butyldimethylsilyl chloride (172.25 g, 1015.6 mmol) and 1H-imidazole (101.3 g, 1472 mmol) at 0°C-5°C. The resulting reaction mixture was stirred at room temperature overnight. When LC / MS and HPLC showed that the reaction was complete, the reaction mixture was quenched with water (1000 mL). The two layers were separated, and the aqueous layer was extracted with dichloromethane (3×500 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to give the crude desired product (18). The crude product was purified on silica gel chromatography (SiO2, eluting with 0-10% ethyl acetate in hexanes) to give the desired product, (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (18, 253.0 g, 87.8% yield over 2 steps) as a yellow to brown oil. About 18: 1 HNMR(300MHz,DMSO-d6)δ8.36(d,J=3.0Hz,1H),7.13(d,J=3.0Hz,1H),5.21(m,1H),3.08(m,1H) ,2.81(m,1H),2.43(m,1H),2.05(m,1H),0.93(s,9H),0.22(s,3H),0.16(s,3H)ppm; LCMS(EI)m / z 284 / 286(C 14 H 22 ClNOSi,(M+H) + ).
[0389] Step 9. (R)-7-(tert-Butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbaldehyde (19)
[0390]
[0391] To a stirred solution of 2,2,6,6-tetramethyl-piperidine (63.0 g, 446 mmol) in anhydrous tetrahydrofuran (THF, 680 mL) was added 2.5 M n-butyllithium in hexane (180 mL, 450 mmol) at -24 to -50 °C. The resulting mixture was warmed to -32 °C and stirred at -32 to 0 °C for 30 minutes, then cooled to -78 °C (external bath). (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine (18, 106.0 g, 373 mmol) in anhydrous tetrahydrofuran (380 mL) was added dropwise to the above mixture cooled at -74 to -76 °C (internal temperature). After the obtained dark brown solution was stirred at -74°C (internal temperature) for 90 minutes, anhydrous N,N-dimethylformamide (DMF, 130 g, 1129 mmol) was added, and the internal temperature was maintained at -76°C to -70°C during the addition. The obtained reaction mixture was continued to be stirred at -74°C to -72°C for 2 hours, then quenched with 1N HCl aqueous solution (500 mL) and water (500 mL). The two phases were separated, and the aqueous phase was extracted with MTBE (2×250 mL). The combined organic phases were washed with brine (2×250 mL) and concentrated under reduced pressure to give a crude product (19). The crude product was purified on silica gel chromatography (SiO2, eluting with 0-8% ethyl acetate in hexanes) to give the desired product, (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbaldehyde (19, 110.7 g, 94% yield) as a yellow to brown oil. 1 HNMR(300MHz, CDCl3)δ10.4(s,1H),8.91(s,1H),5.22(m,1H),3.10(m,1H),2.87(m,1 H),2.48(m,1H),2.09(m,1H),0.92(s,9H),0.21(s,3H),0.16(s,3H)ppm; LCMS(EI)m / z 312 / 314(C 15 H 22 ClNO2Si,(M+H) + ).
[0392] Step 10. (R)-7-(tert-Butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile (20)
[0393]
[0394] Under ice-water bath (internal temperature controlled at 16°C to 22°C), a solution of (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carboxaldehyde (19, 91.3 g, 292 mmol) in tetrahydrofuran (THF, 700 mL) stirred at room temperature was added 14.8 M aqueous ammonia solution (350 mL, 5950 mmol) and iodine (I2, 80.0 g, 315 mmol). The resulting reaction mixture was stirred at room temperature for 3 hours and quenched with 10% aqueous Na2S2O3 solution (200 mL). The mixture was extracted with ethyl acetate (2 500 mL). The combined organic extracts were washed with water (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the desired product, (R)-7-(tert-butyldimethylsilyloxy)-4-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile (20, 89.9 g, 98% yield) as a yellow to brown oil. For 20: 1 H NMR(300MHz, CDCl3)δ8.68(s,1H),5.22(m,1H),3.09(m,1H),2.84(m,1H),2.4 9(m,1H),2.07(m,1H),0.92(s,9H),0.20(s,3H),0.18(s,3H)ppm; LCMS(EI)m / z 309 / 311(C 15 H 21 ClN2OSi,(M+H) + ).
[0395] Example 6
[0396] Stability study of compound 1 phosphate form I
[0397] Compound 1 phosphate Form I was subjected to a variety of different environmental conditions to evaluate stability. The results are shown in Table 2 below. As can be seen from the data, Form I has high stability even in the presence of heat and moisture. Only heating at 210°C showed possible transformation to another solid form, but this transformation was reversible after exposure to 40°C / 75% RH for 4 days.
[0398] Table 2
[0399]
[0400] Example 8
[0401] Preparation of Compound 1 Phosphate Form I
[0402] Procedure A - Isopropyl Alcohol:
[0403] To a solution of compound 1 (25.68 mg, 0.05 mmol) in isopropanol (0.5 mL) was added 0.056 mL of 0.1 M phosphoric acid (0.12 mmol, 1.12 equiv) in isopropanol. The reaction mixture was stirred overnight. The resulting precipitate was collected by filtration, and the filter cake was air-dried to give Form I.
[0404] Procedure B - Acetonitrile:
[0405] Compound 1 (50.35 mg, 0.216 mmol, 1 eq) was combined with 0.1 mL of acetonitrile and the mixture was stirred for 2 minutes to give a clear solution. To the resulting solution was added 0.108 mL of 1 M phosphoric acid (0.108 mmol, 1.1 eq) in isopropanol to give a viscous slurry. The reaction mixture was heated to 78 ° C and stirred for 2 hours (note: slurry), then the reaction mixture was cooled to room temperature and stirred overnight. The resulting precipitate was collected by filtration, and the filter cake was dried to give Form I.
[0406] Karl Fischer titration indicated that the salt of Compound 1 from acetonitrile contained about 1.419% water.
[0407] Procedure C - Ethanol:
[0408] Compound 1 (50.30 mg, 0.216 mmol, 1 equivalent) was combined with 1.2 mL of ethanol, and the mixture was stirred to obtain a clear solution. To the resulting solution was added 0.108 mL of 1 M phosphoric acid (0.108 mmol, 1.1 equivalent) in isopropanol to obtain a slurry. The resulting reaction mixture was heated to 79 ° C and stirred for 2 hours, and then the reaction mixture was stirred at 81 ° C-83 ° C for 2 hours (note: slurry). The reaction mixture was cooled to room temperature and stirred for 2 hours. The resulting precipitate was separated by filtration, and the filter cake was dried to obtain Form I (55 mg, 91.8%).
[0409] Procedure D - Methanol:
[0410] Compound 1 (50 mg, 0.216 mmol, 1 eq) was combined with 0.5 mL of methanol to give a clear solution. To the resulting solution was added 0.95 mL of 1 M phosphoric acid (0.95 mmol, 1.25 eq) in isopropanol to give a viscous slurry. Methanol (0.5 mL) was added and the mixture was stirred for 1 hour, then the reaction mixture was heated to 78 ° C and stirred at this temperature for 2 hours (caution: slurry). The resulting precipitate was collected by filtration, and the filter cake was dried to give Form I (42.6 mg, 91.7%).
[0411] The stoichiometric ratio between the free base of compound 1 and phosphoric acid was determined to be 1:1 by elemental analysis. Elemental analysis: C 26 H29 Calculated values for F3N5O7P: C, 51.07; H, 4.78; N, 11.45; P, 5.07. Found values: C, 49.23; H, 4.57; N, 10.85; P, 5.28.
[0412] Example 9
[0413] Stability study of compound 1 phosphate form I at 25°C and 50°C under phase equilibrium conditions
[0414] Phase equilibrium studies were designed to provide information about the major crystalline forms for phase identification. Compound 1 phosphate (Form I) was prepared in a panel of representative solvents at 25 ± 1 °C (chloroform, DMF, 1,4-dioxane, methanol and methanol / 20% water, 2-methoxyethanol and 2-methoxyethanol / 20% water, MIBK, THF and THF / 20% water, acetone, n-BuOH and n-BuOH / 20% water, EtOH and EtOH / 20% water, isobutyl acetate, 1-propanol and 1-propanol / 20% water, isopropanol, water, and MEK) and 50 ± 1 °C (chloroform, DMF , 1,4-dioxane, methanol and methanol / 20% water, 2-methoxyethanol and 2-methoxyethanol / 20% water, MIBK, THF and THF / 20% water, acetone, n-BuOH and n-BuOH / 20% water, EtOH and EtOH / 20% water, EtOAc, ethyl formate, 1-propanol and 1-propanol / 20% water, isopropanol, IPA / MeOH / water (1.73 / 0.79 / 0.08), IPA / water (3 / 2), water) and the temperature was balanced by ETS-D5 temperature controller and RCT basic safety control is used for control.
[0415] Compound 1 phosphate (Form I) was added to 3 mL of solvent or solvent mixture (selected from the list of corresponding temperatures) until a turbid solution was obtained, followed by addition of about 30 mg of Compound 1 phosphate (Form I) to the turbid solution. The mixture was stirred at 25 ± 1 ° C or 50 ± 1 ° C for 2-3 days, respectively. The solid was filtered and analyzed by XRPD. The substance is Form I for phase equilibrium at 25 ± 1 ° C and 50 ± 1 ° C in all solvents and solvent mixtures tested, which is the same as the starting material Compound 1 phosphate (Form I).
[0416] Example 10
[0417] Preparation and characterization of compound 1 phosphate form II
[0418] A saturated solution of Compound 1 Phosphate Form I (prepared in Example 1, 20 mL) in DMF was evaporated under air at 25±1° C. without stirring to give a solid that was characterized by XRPD, DSC and TGA to be Form II.
[0419] The experimental parameters used to obtain the XRPD data were as described in Example 2. Figure 7 The XRPD pattern is shown in and the XRPD data are provided in Table 3.
[0420] Table 3. Form II XRPD Data
[0421]
[0422]
[0423] The experimental parameters used to obtain the DSC data were as described in Example 3. Figure 8 The DSC thermogram is shown in and exhibits an endothermic event at about 249°C.
[0424] The experimental parameters used to obtain TGA data are as described in Example 4. Fig. 9 The TGA thermal analysis diagram is shown in FIG.
[0425] Embodiment 11
[0426] Preparation and characterization of compound 1 phosphate form III
[0427] 20 mL of a saturated solution of Compound 1 phosphate (Form I) in DMF was evaporated under air at 50±1° C. without stirring to give a solid that was characterized by XRPD, DSC and TGA to be Form III.
[0428] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.10 The XRPD pattern is shown in and the XRPD data are provided in Table 4.
[0429] Table 4. Form III XRPD Data
[0430] 2θ(°) high H% 4.6 425 85.1 7.1 50 9.9 9.4 129 25.9 13.3 166 33.3 15.7 89 17.8 16.3 173 34.7 18.9 500 100 19.2 289 57.9 21.2 290 58 22.5 220 44.1 23.1 216 43.2 24.3 88 17.7 24.9 142 28.4 25.6 65 13.1 26.7 165 33.1 27.7 89 17.7 29.1 61 12.1 30.4 62 12.4 33.4 41 8.2 34.2 66 13.2 35.0 72 14.3 38.3 46 9.3 38.8 57 11.5 43.4 43 8.7
[0431] The experimental parameters used to obtain the DSC data were as described in Example 3. Fig.11 The DSC thermogram is shown in and exhibits an endothermic event at about 250°C.
[0432] The experimental parameters used to obtain TGA data are as described in Example 4. Fig.12 The TGA thermal analysis diagram is shown in FIG.
[0433] Example 12
[0434] Preparation and characterization of compound 1 phosphate form IV
[0435] 20 mL of a saturated solution of Compound 1 phosphate Form I in water was evaporated under air at 50 ± 1 °C without stirring to give a solid that was characterized by XRPD, DSC and TGA to be Form IV.
[0436] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.13 The XRPD pattern is shown in and the XRPD data are provided in Table 5.
[0437] Table 5. Form IV XRPD Data
[0438] 2θ(°) high H% 4.1 81 62.1 4.9 52 39.9 6.9 45 34.7 7.4 63 48.3 8.0 37 28.6 11.0 44 34 12.8 38 29 13.3 96 73.9 16.4 130 100 17.7 78 59.4 18.1 88 67.1 18.6 102 77.8 19.0 55 42 19.8 118 90.1 20.6 42 32.3 21.4 114 87 22.6 46 35.5 23.3 81 62 25.0 61 46.8 26.7 46 35.5 35.7 26 20.2 38.4 27 20.3
[0439] The experimental parameters used to obtain the DSC data were as described in Example 3. Fig.14 The DSC thermogram is shown in and exhibits an endothermic event at about 245 °C.
[0440] The experimental parameters used to obtain TGA data are as described in Example 4. Fig.15 The TGA thermal analysis diagram is shown in FIG.
[0441] Embodiment 13
[0442] Preparation and characterization of compound 1 phosphate form V
[0443] 100 mL of a saturated solution of Compound 1 phosphate in water prepared at 35°C was chilled to 4-5°C and maintained at this temperature for 1 hour to give a thin slurry, which was filtered and air dried for 1 hour. The solid was determined to be Compound 1 phosphate Form V and was characterized by XRPD, DSC, and TGA.
[0444] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.16 The XRPD pattern is shown in and the XRPD data are provided in Table 6.
[0445] Table 6. Form V XRPD Data
[0446]
[0447]
[0448] The experimental parameters used to obtain the DSC data were as described in Example 3. Fig.17 The DSC thermogram is shown in FIG.
[0449] The experimental parameters used to obtain TGA data are as described in Example 4. Fig.18 The TGA thermal analysis diagram is shown in FIG.
[0450] Embodiment 14
[0451] Preparation and characterization of compound 1 phosphate form VI
[0452] Compound 1 phosphate was added to 150 mL of water to give a slurry which was stirred for 2 hours to give a suspension. The suspension was filtered and the filtrate was cooled to 4-5° C. and maintained at 4-5° C. for 3 days. The suspension was filtered to isolate a crystalline solid which was characterized by XRPD, DSC and TGA to be Form VI.
[0453] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.19 The XRPD pattern is shown in and the XRPD data are provided in Table 7.
[0454] Table 7. Form VI XRPD Data
[0455]
[0456]
[0457] The experimental parameters used to obtain the DSC data were as described in Example 3. Fig. 20 The DSC thermogram is shown in FIG.
[0458] The experimental parameters used to obtain TGA data are as described in Example 4. Fig.21 The TGA thermal analysis diagram is shown in FIG.
[0459] Embodiment 15
[0460] Polymorphic Phenomenon of Compound 1 Phosphate Using Antisolvent Addition
[0461] Saturated solutions of Compound 1 phosphate were prepared by adding Compound 1 phosphate (Form I) to DMF, MeOH, MeOH / 20% water, and DMSO, respectively. Antisolvents were added to induce precipitation. MTBE, IPAc, EtOAc, MeCN, MIBK, MEK, and toluene were selected as antisolvents. Experiments that did not produce any particulate solids upon addition of antisolvents were not further studied.
[0462] In anti-solvent addition (see Table 8), Form I was identified from MeOH / IPAc, MeOH / EtOAc, MeOH / MEK, aqueous MeOH / MTBE, DMSO / MeCN, DMSO / IPAc, and DMSO / MEK. Form II was identified from MeOH / MeCN, aqueous MeOH / MeCN, and aqueous MeOH / IPAc. Amorphous forms were found from MeOH / TBME and MeOH / MIBK.
[0463] Fig.23 The XRPD pattern of amorphous Compound 1 phosphate salt is shown in FIG.
[0464] Table 8
[0465] Solvent (mL) Antisolvent (mL) Solid form DMF (2 mL) IPAc (8 mL) n / a DMF (2 mL) MTBE (8 mL) n / a MeOH (2 mL) MTBE (8 mL) Amorphous MeOH (2 mL) IPAc (8 mL) Form I MeOH (2 mL) EtOAc (8 mL) Form I MeOH (2 mL) <![CDATA[CH2Cl2(8mL)]]> clear solution MeOH (2 mL) MeCN (8 mL) Form II MeOH (2 mL) MIBK (8 mL) Amorphous MeOH (2 mL) MEK(8mL) Form I MeOH / 20% water (2 mL) MeCN (8 mL) Form II MeOH / 20% water (2 mL) MTBE (8 mL) Form I MeOH / 20% water (2 mL) IPAc (8 mL) Form II DMSO (0.5 mL) MeCN (5 mL) Form I DMSO (0.5 mL) IPAc (5 mL) Form I DMSO (0.5 mL) MEK (5.5 mL) Form I DMSO (0.5 mL) Acetone (8 mL) n / a DMSO (0.5 mL) Toluene (6 mL) n / a
[0466] Example 16
[0467] Polymorphic study of the phosphate salt of compound 1 using reverse addition
[0468] Saturated solutions of Compound 1 phosphate salt were prepared in DMF, MeOH, MeOH / 20% water, and DMSO listed in Table 9 and added to larger volumes of miscible antisolvents (i.e., MTBE, IPAc, EtOAc, MeCN). Experiments that did not produce any particulate solids upon addition to the antisolvent were not investigated further. Form I was identified from most solvents, except for Form II from MeOH / MeCN, aqueous MeOH / MeCN, and aqueous MeOH / IPAc. Amorphous solids were identified from MeOH / MTBE, MeOH / EtOAc, and MeOH / MIBK.
[0469] Table 9
[0470] Solvent (mL) Antisolvent (mL) Solid form DMF (2 mL) IPAc (8 mL) n / a DMF (2 mL) MTBE (8 mL) n / a MeOH (2 mL) MTBE (8 mL) Amorphous MeOH (2 mL) IPAc (8 mL) Form I MeOH (2 mL) EtOAc (8 mL) Amorphous MeOH (2 mL) <![CDATA[CH2Cl2(8mL)]]> n / a MeOH (2 mL) MeCN (8 mL) Form II MeOH (2 mL) MIBK (8 mL) Amorphous MeOH (2 mL) MEK(8mL) Form I MeOH / 20% water (2 mL) MeCN (8 mL) Form II MeOH / 20% water (2 mL) MTBE (8 mL) Form I MeOH / 20% water (2 mL) IPAc (8 mL) Form II DMSO (0.5 mL) IPAc (5 mL) Form I DMSO (0.5 mL) MeCN (5 mL) Form I DMSO (0.5 mL) MEK (5.5 mL) Form I DMSO (0.5 mL) Acetone (8 mL) n / a DMSO (0.5 mL) Toluene (6 mL) n / a
[0471] Embodiment 17
[0472] Phosphate studies of compound 1 using quenching
[0473] A saturated solution of Compound 1 phosphate prepared at 35°C was quenched to about -20°C to -25°C to induce precipitation of a higher energy crystalline form. Representative solvents were selected based on solubility data measured at 25°C and 50°C (see Example 7). The solvents studied and the crystalline forms produced by the experiments are shown in Table 10. Form I was identified from aqueous THF and aqueous EtOH. Forms V and VI were identified from water.
[0474] Table 10
[0475] Solvent (mL) Solid form DMF clear solution MeOH clear solution MeOH / 20% water clear solution 2-Methoxyethanol clear solution 2-Methoxyethanol / 20% water clear solution THF / 20% water Form I EtOH / 20% water Form I 1-PrOH / 20% water clear solution 2-PrOH / 20% water clear solution Water (cooled to 4℃-5℃) Form V Water (cooled to 4℃-5℃) Form VI
[0476] Embodiment 18
[0477] Polymorphic studies of the phosphate salt of compound 1 using heating and cooling procedures
[0478] This experiment is designed to find a stable crystalline form. A saturated solution was prepared at 50 ° C, and all solvents were cooled slowly in the bath using a programmed circulating bath to obtain a clear solution. About 10 mg of compound 1 phosphate form I was added to the clear solution to obtain a slurry. The resulting slurry was then heated to 50 ° C for 2 hours and then cooled to 5 ° C for 2 hours. This process was repeated for 3 days, and the solid was filtered for further analysis. The results are presented in Table 11. For all samples, Form I was identified.
[0479] Table 11
[0480]
[0481]
[0482] Embodiment 19
[0483] Polymorphic studies of the phosphate salt of compound 1 using evaporation
[0484] Evaporation studies were performed to identify the major crystalline form during uncontrolled precipitation. Experiments that did not produce any particulate solids (i.e., clear films and oils) were not further investigated (n / a). XRPD was used to characterize the ETS-D5 temperature controller and RCT based safety control is used to control the solid state morphology of the crystalline form of the evaporated samples at 25±1℃ and 50±1℃.
[0485] The results are presented in Table 12 (25 ± 1 ° C) and Table 13 (50 ± 1 ° C). Evaporation at 25 ± 1 ° C (Table 12) produced polymorphic Form II (DMF). Evaporation at 50 ± 1 ° C (Table 13) produced two polymorphic forms, including Form III (DMF) and Form IV (water).
[0486] Table 12. Evaporation at 25 ± 1 °C
[0487]
[0488]
[0489] Table 13. Evaporation at 50±1°C
[0490]
[0491]
[0492] Embodiment 20
[0493] Competitive stability study of phosphate crystalline solid of compound 1 in IPA / MeOH / water / DMSO
[0494] To evaluate the conversion of Compound 1 phosphate solid form, a competitive slurry experiment was performed as follows: Form I (6 mg) was added to a saturated solution (1.5 mL) of Compound 1 phosphate Form I in a solvent as listed in Table 14, followed by stirring to give a turbid solution, and then 6 mg each of Form II to Form VI was added to the mixture. The slurry was stirred at room temperature for 2 days and analyzed by XRPD. The results in Table 14 reveal that Compound 1 phosphate Form I appears to be the most stable form in either of the IPA / methanol / water / DMSO mixtures.
[0495] Table 14
[0496] Solvent (mL) Solid form IPA / MeOH / water / DMSO(61.8 / 28.2 / 2.9 / 7.1) Form I IPA / MeOH / water / DMSO(56.6 / 28.3 / 3.0 / 12.1) Form I
[0497] Embodiment 22
[0498] Karl Fischer titration of crystalline solid form of compound 1 phosphate
[0499] The results of Karl Fischer titration of Compound 1 phosphate polymorphic Forms I-VI are presented in Table 15.
[0500] Table 15
[0501]
[0502]
[0503] Karl Fischer analysis of Compound 1 phosphate salt Forms I-VI was performed. Each experiment revealed that the water content ranged from 1.40% to 15.9%, indicating that each of Forms I-VI may be a hydrate.
[0504] Embodiment 23
[0505] Preparation and characterization of compound 1 dihydrochloride
[0506] Compound 1 (55.2 mg, 0.107 mmol) was combined with 0.7 mL of isopropyl alcohol (IPA) and stirred for 2 minutes to give a clear solution. Hydrochloric acid solution (0.25 mL, 0.25 mmol, 2.34 equiv; 1 M HCl in IPA / IPAc from 3.7 M HCl in IPAc) was added to give a slurry, which was heated to 50 °C and stirred for 15 minutes. The resulting mixture was cooled to room temperature, stirred overnight, filtered and dried under vacuum (6 hours) to give the final product (61.8 mg, 98%).
[0507] The stoichiometric ratio between compound 1 and hydrochloric acid was determined to be 1:2 by elemental analysis. 1 H NMR indicated that the salt contained 7.8% isopropanol, and Karl-Fischer titration indicated that the water content was about 0.586%. Elemental analysis: C 29 H 35 Calculated values for Cl2F3N5O4: C, 53.67; H, 5.35; N, 10.80; Cl, 10.95. Found values: C, 53.26; H, 5.21; N, 10.57; Cl, 10.83.
[0508] Compound 1 dihydrochloride was characterized by XRPD, DSC and TGA. The experimental parameters used to obtain the XRPD data were as described in Example 2. Figure 4 The XRPD pattern is shown in . The experimental parameters used to obtain the DSC data are as described in Example 3. Figure 5 The DSC thermogram is shown in . The DSC thermogram reveals a major endothermic peak at about 213° C. The experimental parameters used to obtain TGA data are as described in Example 4. Figure 6 The TGA thermal analysis diagram is shown in FIG.
[0509] XRPD data is provided in Table 17.
[0510] Table 17
[0511]
[0512]
[0513] Embodiment 24
[0514] Preparation and characterization of compound 1 monohydrochloride
[0515] To a solution of compound 1 free base (see Example 1, step 6; 0.05 mmol, 25.68 mg) in isopropanol (0.5 mL, 0.1 M) was added 0.056 mL of hydrochloric acid (0.056 mmol, 1.12 equiv., 1.0 M IPA / IPAc solution, prepared from 3.7 M HCl in IPAc (isopropyl acetate)). The reaction mixture was stirred overnight. The resulting precipitate was removed by filtration, and the filter cake was washed with MTBE and the solid was dried in vacuo overnight to give the title salt.
[0516] Compound 1 monohydrochloride was characterized by XRPD and DSC. Fig. 22 The XRPD pattern is provided in . The experimental parameters used to obtain the DSC data are as described in Example 3. Fig.23 The DSC thermogram is shown in FIG.
[0517] XRPD data is provided in Table 18.
[0518] Table 18
[0519] 2θ(°) high H% 3.5 102 27.3 4.0 105 28 7.8 126 33.6 8.8 134 35.7 11.9 57 15.3 12.6 121 32.2 14.5 138 36.8 15.0 47 12.5 15.9 70 18.8 16.6 44 11.6 17.4 113 30.2 19.7 74 19.8 20.4 59 15.8 20.6 54 14.4 22.3 74 19.9 23.8 186 49.6 24.6 84 22.3 25.2 375 100 26.3 80 21.4 26.5 82 21.8 27.4 38 10.2 28.8 90 24 29.2 72 19.2 31.1 75 19.9 31.5 44 11.7 31.7 42 11.3 34.5 69 18.3 37.6 46 12.4 40.9 43 11.4 41.3 32 8.6 41.8 34 8.9
[0520] Embodiment 25
[0521] Preparation and characterization of maleic acid salt of compound 1
[0522] 1.0mL volume of isopropanol is added to compound 1 free base (50.30mg, 0.216mmol, 1 equivalent). Stir the resulting mixture to obtain a clear solution. Maleic acid (14.2mg, 0.122mmol, 1.21 equivalents) is added to this solution, and the resulting reaction mixture is stirred to obtain a clear solution. Continue stirring for 1 hour. Add 1mg of crystals (seeds) obtained from IPA / heptane to this solution, and stir the resulting mixture to obtain a slurry. Stir the slurry continuously for 3 hours. Remove the precipitate by filtration, and wash the filter cake with MTBE and vacuum dry overnight to obtain the title salt (56.8mg, 89.2%).
[0523] The stoichiometric ratio between the free base of compound 1 and maleic acid in the salt is determined by 1 H NMR confirmed 1: 1. The crystallinity of the maleic acid salt of Compound 1 was confirmed by XRPD, DSC and TGA.
[0524] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.24 The XRPD pattern is shown in . The experimental parameters used to obtain the DSC data are as described in Example 3. Fig.25 The DSC thermogram is shown in . The experimental parameters used to obtain TGA data are as described in Example 4. Fig.26 The TGA thermal analysis diagram is shown in FIG.
[0525] The XRPD data are provided in Table 19.
[0526] Table 19
[0527]
[0528]
[0529] Embodiment 26
[0530] Preparation and characterization of adipate salt of compound 1
[0531] 0.6mL volume of isopropanol was added to compound 1 free base (37.8mg, 0.216mmol, 1 equivalent) and the resulting mixture was stirred for 1 minute to obtain a clear solution. Adipic acid (26.8mg, 0.183mmol, 2.49 equivalents) was added to the solution and the resulting slurry was stirred at room temperature for 5 minutes. The reaction mixture was heated to 50°C and stirred for 15 minutes at the temperature. (Note: clear solution). The reaction mixture was cooled to room temperature and stirred for 3 hours. Heptane (0.2mL) was added and the reaction mixture was stirred to obtain a slurry, which was stirred continuously overnight. The precipitate was removed by filtration, and the filter cake was washed with MTBE, collected and vacuum dried overnight to obtain the title salt (36.5mg, yield 84.5%).
[0532] The stoichiometric ratio between the free base of compound 1 and adipic acid in the salt is determined by 1 HNMR determined to be 1:1. The crystallinity of Compound 1 adipate salt was confirmed by XRPD, DSC and TGA. The experimental parameters used to obtain XRPD data were as described in Example 2. Fig. 27 The XRPD pattern is shown in . The experimental parameters used to obtain the DSC data are as described in Example 3. Fig.28 The DSC thermogram is shown in . The experimental parameters used to obtain TGA data are as described in Example 4. Fig.29 The TGA thermal analysis diagram is shown in FIG.
[0533] The XRPD data are provided in Table 20.
[0534] Table 20
[0535]
[0536]
[0537] Embodiment 27
[0538] Preparation and characterization of compound 1 hydrobromide
[0539] To a 0.1M solution of compound 1 free base (0.05mmol, 25.68mg) in isopropanol (0.5mL) was added 0.12mL of hydrobromic acid (0.12mmol, 2.4 equivalents, 1.0M solution in isopropanol / water). The resulting mixture was stirred overnight to give a slurry. The precipitate was removed by filtration, and the filter cake was washed with MTBE and dried in vacuo overnight to give the desired product.
[0540] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.30 The XRPD pattern is shown in . The experimental parameters used to obtain the DSC data are as described in Example 3. Fig.31The DSC thermogram is shown in . The experimental parameters used to obtain TGA data are as described in Example 4. Fig.32 The TGA thermal analysis diagram is shown in FIG.
[0541] XRPD data is provided in Table 21.
[0542] Table 21
[0543]
[0544]
[0545] Embodiment 28
[0546] Preparation and characterization of compound 1 mandelate salt
[0547] To a 0.1M solution of Compound 1 free base (0.05 mmol, 25.68 mg) in IPA (0.5 mL) was added mandelic acid (8.1 mg, 0.053 mmol, 1.06 equiv). The mixture was stirred overnight. The slurry was filtered and washed with MTBE to give Compound 1 mandelate salt, which was analyzed by XRPD, DSC, and TGA.
[0548] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.33 The XRPD pattern is shown in . The experimental parameters used to obtain the DSC data are as described in Example 3. Fig.34 The DSC thermogram is shown in . The experimental parameters used to obtain TGA data are as described in Example 4. Fig.35 The TGA thermal analysis diagram is shown in FIG.
[0549] XRPD data is provided in Table 22.
[0550] Table 22
[0551]
[0552]
[0553] Embodiment 29
[0554] Compound 1 Salicylate
[0555] Salicylic acid (0.058 mmol, 8.01 mg, 1.16 equiv) was added to a 0.1 M solution of compound 1 free base (0.05 mmol, 25.68 mg) in isopropanol (IPA) (0.5 mL). The resulting reaction mixture was stirred overnight to form a slurry. The precipitate was removed by filtration, and the filter cake was washed with methyl tert-butyl ether (MTBE) to give compound 1 salicylate, which was characterized by XRPD and DSC.
[0556] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.36 The XRPD pattern is shown in . The experimental parameters used to obtain the DSC data are as described in Example 3. Fig.37 The DSC thermogram is shown in FIG.
[0557] XRPD data is provided in Table 23.
[0558] Table 23
[0559]
[0560]
[0561] Embodiment 30
[0562] Compound 1 Benzoate
[0563] To a 0.1M solution of compound 1 free base (0.05 mmol, 25.68 mg) in isopropanol (IPA) (0.5 mL) was added benzoic acid (7.05 mg, 0.0577 mmol, 1.16 equiv). The resulting reaction mixture was stirred overnight to form a slurry. The precipitate was removed by filtration, and the filter cake was washed with methyl tert-butyl ether (MTBE) to give compound 1 benzoate, which was analyzed by XRPD.
[0564] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.38 The XRPD pattern is shown in FIG.
[0565] XRPD data is provided in Table 24.
[0566] Table 24
[0567]
[0568]
[0569] Embodiment 31
[0570] Compound 1 benzenesulfonate
[0571] To a 0.1 M solution of compound 1 free base (0.05 mmol, 25.68 mg) in isopropanol (IPA) (0.5 mL) was added benzenesulfonic acid (0.11 mL of a 0.5 M solution in isopropanol, 0.055 mmol, 1.1 equiv). The resulting reaction mixture was stirred overnight to give a slurry. The precipitate was removed by filtration to give compound 1 benzenesulfonate salt, which was characterized by XRPD.
[0572] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.39 The XRPD pattern is shown in FIG.
[0573] XRPD data is provided in Table 25.
[0574] Table 25
[0575]
[0576]
[0577] Embodiment 32
[0578] Compound 1L-pyroglutamate
[0579] To a solution of 0.1M compound 1 free base (0.05mmol, 25.68mg) in isopropanol (IPA) (0.5mL) was added L-pyroglutamic acid (7.25mg, 0.056mmol, 1.12 equivalents). The resulting reaction mixture was stirred for 5 hours, and then heptane (0.3mL) was added. The reaction mixture was stirred continuously overnight to form a slurry. The precipitate was removed by filtration, and the filter cake was washed with methyl tert-butyl ether (MTBE) to give compound 1 L-pyroglutamate, which was characterized by XRPD.
[0580] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.40 The XRPD pattern is shown in FIG.
[0581] XRPD data is provided in Table 26.
[0582] Table 26
[0583] 2θ(°) high H% 4.4 344 32.7 8.3 49 4.6 9.2 86 8.2 10.7 343 32.6 11.5 1052 100 12.5 74 7.1 13.5 176 16.7 15.0 102 9.7 15.4 202 19.2 16.1 100 9.5 17.5 73 6.9 18.0 365 34.7 19.0 145 13.8 19.8 72 6.8 20.7 576 54.7 21.2 706 67.1 22.9 539 51.2 23.7 66 6.3 24.5 139 13.2 25.2 98 9.3 26.4 124 11.8 29.2 158 15 32.4 85 8.1 33.0 47 4.4 34.0 49 4.6 41.3 51 4.9 41.9 46 4.4
[0584] Embodiment 33
[0585] Compound 1 Methanesulfonate
[0586] Methanesulfonic acid (0.055mmol, 1.1 equivalents, 0.055mL 1.0M EtOH solution) is added to a solution of 0.1M compound 1 free base (0.05mmol, 25.68mg) in isopropanol (IPA) (0.5mL). The resulting reaction mixture is stirred for 5 hours, and then heptane (0.3mL) is added to the reaction mixture. The reaction mixture is stirred continuously for 24 hours to obtain a slurry. The precipitate is removed by filtration to obtain compound 1 mesylate, which is analyzed by XRPD.
[0587] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.41 The XRPD pattern is shown in FIG.
[0588] XRPD data is provided in Table 27.
[0589] Table 27
[0590]
[0591]
[0592] Embodiment 34
[0593] Compound 1 (1S)-(+)-10-Camphorsulfonate
[0594] To a solution of 0.1M compound 1 free base (0.05mmol, 25.68mg) in isopropanol (IPA) (0.5mL) was added (1S)-(+)-10-camphorsulfonic acid (0.055mmol, 1.1 equivalents, 0.11mL 0.5M IPA solution) (CAS Reg. No. 3144-16-9; Aldrich Catalog No. C2107-500G). The resulting reaction mixture was stirred for 5 hours, and then heptane (0.3mL) was added to the reaction mixture. The reaction mixture was stirred continuously overnight to obtain a slurry. The precipitate was removed by filtration to obtain compound 1 camphorsulfonate, which was analyzed by XRPD.
[0595] The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.42 The XRPD pattern is shown in FIG.
[0596] XRPD data is provided in Table 28.
[0597] Table 28
[0598]
[0599]
[0600] Embodiment 35
[0601] Compound 1 Fumarate
[0602] Maleic acid (6.69 mg, 0.058 mmol, 1.16 equivalents) was added to a solution of 0.1 M compound 1 free base (0.05 mmol, 25.68 mg) in isopropanol (IPA) (0.5 mL). The reaction mixture was stirred for 5 hours, and then heptane (0.3 mL) was added to the reaction mixture. The reaction mixture was stirred continuously overnight to obtain a slurry. The precipitate was removed by filtration to obtain compound 1 fumarate, which was analyzed by XRPD.
[0603] Compound 1 fumarate salt was characterized by XRPD. The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.43 The XRPD pattern is shown in FIG.
[0604] XRPD data is provided in Table 29.
[0605] Table 29
[0606]
[0607]
[0608] Embodiment 36
[0609] Compound 1 Sulfate
[0610] To a 0.1 M solution of Compound 1 free base (0.05 mmol, 25.68 mg) in IPA (0.5 mL) was added sulfuric acid (0.055 mmol, 1.1 eq., 0.055 mL of a 1.0 M IPA solution). The reaction mixture was stirred overnight to give a slurry. The precipitate was removed by filtration to give Compound 1 sulfate, which was characterized by XRPD.
[0611] Compound 1 sulfate was characterized by XRPD. The experimental parameters used to obtain the XRPD data were as described in Example 2. Fig.44 The XRPD pattern is shown in FIG.
[0612] XRPD data is provided in Table 30.
[0613] Table 30
[0614]
[0615]
[0616] Embodiment 37
[0617] Compound 1L-tartrate
[0618] To a solution of 0.1M compound 1 free base (0.05mmol, 25.68mg) in isopropanol (IPA) (0.5mL) was added L-tartaric acid (8.71mg, 0.058mmol, 1.16 equivalents). The reaction mixture was stirred for 5 hours, and then heptane (0.3mL) was added to the reaction mixture. The reaction mixture was stirred continuously overnight to obtain a slurry. The precipitate was removed by filtration to obtain compound 1 L-tartrate, which was analyzed by XRPD.
[0619] Compound 1 L-tartrate salt was obtained as an amorphous solid. The experimental parameters used to obtain XRPD data were as described in Example 2. Fig.45 The XRPD pattern is shown in FIG.
[0620] Embodiment 38
[0621] Compound 1D-tartrate
[0622] D-tartaric acid (8.64 mg, 0.058 mmol, 1.16 equivalents) was added to a solution of 0.1 M compound 1 free base (0.05 mmol, 25.68 mg) in IPA (0.5 mL). The reaction mixture was stirred for 5 hours, and then heptane (0.3 mL) was added to the reaction mixture. The reaction mixture was stirred continuously overnight to obtain a slurry. The precipitate was removed by filtration to obtain compound 1 D-tartrate, which was analyzed by XRPD.
[0623] Compound 1D-tartrate was obtained as an amorphous solid ( Fig.46 XRPD pattern is shown in ).
[0624] Example A
[0625] Pim enzyme assay
[0626] Pim-1 and Pim-3 kinase assays - 20 μL reactions can be performed in white 384-well polystyrene plates spotted with 0.8 μL compound / DMSO in assay buffer (50 mM Tris pH 7.5, 0.01% Tween-20, 5 mM MgCl2, 0.01% BSA, 5 mM DTT) containing 0.05 μM biotinylated BAD peptide substrate (AnaSpec62269), 1 mM ATP and 2.5 pM (Pim-1, Invitrogen PV3503) or 1.25 pM (Pim-3, Millipore 14-738) enzyme for 1 hour at 25°C. The reaction was stopped by adding 10 μL of stop buffer (150 mM Tris pH=7.5, 150 mM NaCl, 75 mM EDTA, 0.01% Tween-20, 0.3% BSA) supplemented with 666-fold diluted phospho-Bad (Ser112) antibody (Cell Signaling 9291) and streptavidin donor beads (PerkinElmer 6760002) and protein-A acceptor beads (PerkinElmer 6760137), each at 15 μg / mL. Stop buffer was supplemented with beads and the reaction was stopped under reduced light. Before stopping the reaction, the stop buffer with beads was pre-incubated at room temperature in the dark for 1 hour. After stopping the reaction, the plate was incubated at room temperature in the dark for 1 hour and then read under reduced light on a PHERAstar FS plate reader (BMGLabtech).
[0627] Pim-2 Kinase Assay - 20 μL reactions were performed at 25°C for 2 hours in white 384-well polystyrene plates spotted with 0.8 μL compound / DMSO in assay buffer (50 mM Tris pH 7.5, 0.01% Tween-20, 5 mM MgCl2, 0.01% BSA, 5 mM DTT) containing 0.05 μM fluorescein-labeled CREBtide peptide substrate (Invitrogen PV3508), 1 mM ATP and 1 nM enzyme (Invitrogen PV3649). The reaction was stopped by adding 10 μL TR-FRET dilution buffer (Invitrogen PV3574) with 30 mM EDTA and 1.5 nM LanthaScreen Tb-CREB pSer133 antibody (Invitrogen PV3566). After incubation at room temperature for 30 minutes, the plates were read on a PHERAstar FS plate reader (BMG Labtech).
[0628] When tested for PIM kinase activity under the assay conditions disclosed above, the IC values were 2 μM or less. 50 Compounds or salts of the invention of 1% to 1% are considered active. Compound 1 was tested according to this assay and IC 50 <100 nM. Compound 1 phosphate and Compound 1 dihydrochloride were tested according to this assay and the data are provided in Table 16 below.
[0629] Although the above in vitro assays were performed at 1 mM ATP, it is also possible to target PIM targets using K m Conditions to evaluate compound performance and in vitro activity, where ATP concentration was set as K m values and the assay is more sensitive to PIM inhibitory activity.
[0630] Example B
[0631] Pim cell and whole blood assays
[0632] Pim cell proliferation assay
[0633] KMS12BM and MOLM16 cells are purchased from DSMZ (Germany) and are maintained according to the advice of the supplier. In order to measure the antiproliferative activity of test compounds, cells are plated in 96-well ultra-low binding plates (Corning) in its corresponding culture medium (2 × 103 cells / 200 μ L / hole), with or without test compounds. After 3 to 4 days, then the PBS (10 μ L) containing [3H]-thymidine (1 μ Ci / hole) (PerkinElmer) is added to the cell culture, continues other 12 hours, then filtered with water through GF / B filter (Packard Bioscience), separates the radioactivity incorporated, and measures by carrying out liquid scintillation counting with TopCount (Packard Bioscience).
[0634] Pim pBAD signaling assay
[0635] To measure the effect of the test compounds on the pBAD level in cells, KMS12BM cells (DSMZ, Germany) were cultured with RPMI and 10% FBS (4 × 10 5 Cells were plated in 96-well v-bottom polypropylene plates (Greiner) at 100 μL of 10% CO2. After 2.5 h at 37°C and 5% CO2, cells were lysed in 100 μL of cell extraction buffer (Cell Signaling Technology) containing PMSF, HALT and protease inhibitors (Thermo, EMD Calbiochem). pBAD protein in cell lysates was quantified using a human pBAD S112 ELISA kit (Cell Signaling Technology). IC was determined by fitting a curve of percent inhibition versus logarithm of inhibitor concentration using GraphPad Prism 5.0 software. 50 .
[0636] To measure the effect of test compounds on pBAD levels in cells in the presence of human whole blood, human heparinized whole blood (Biological Specialty Corp, Colmar PA) was obtained and added to 96-well 2 mL blocking plates (Costar 3961) at 350 μL / well in the presence or absence of 20 μL of a concentration range of test compounds. 6 ) or MOLM-16 cells (5×10 5) (DSMZ, Germany) was added to each well. After 2.5 hours at 37°C and 5% CO2, erythrocytes were lysed with erythrocyte lysis buffer (Qiagen) and residual cells were centrifuged at 1200RPM. The resulting pellet was dissolved with 100μL of cell extraction buffer (Cell Signaling Technology) containing Halt, PMSF and protease inhibitors (Thermo, Calbiochem, Sigma). The pBAD protein level in the cell lysate was then quantified in a commercially available human pBADS112 ELISA kit (Cell Signaling Technology). IC was determined by fitting a curve of inhibition percentage versus the logarithm of inhibitor concentration using GraphPad Prism 5.0 software. 50 .
[0637] Example C
[0638] Measurement data
[0639] Both Compound 1 phosphate and Compound 1 dihydrochloride were tested in the above assays of Example A and Example B. The data is provided in Table 30 below.
[0640] Table 30
[0641]
[0642]
[0643] In addition to the description herein, various modifications of the present invention will be apparent to those skilled in the art from the above description. It is also intended that such modifications are within the scope of the appended claims. Each reference cited in this application, including (but not limited to) all patents, patent applications and publications are incorporated herein by reference in their entirety.
Claims
1. A solid form of a salt having the formula: wherein the solid form is crystalline Form I having characteristic XRPD peaks according to 2θ comprising the following: 4.6°, 9.4°, 13.1°, 16.2°, 17.4°, 17.9°, 18.8°, 19.4°, 21.1°, 23.0°, 24.8° and 25.2°, wherein the peaks may vary by ±0.2° (2θ).
2. The solid form of claim 1 which is a hydrate.
3. The solid form of claim 2 which is a hemihydrate.
4. The solid form of claim 1 having an endothermic event at 198°C or 250°C, wherein the endothermic event can vary by ±3°C.
5. The solid form of claim 1 having an XRPD pattern substantially as depicted in Figure 1.
6. The solid form of claim 1 having a melting point of 250°C, wherein the melting point may vary by ±3°C.
7. The solid form of claim 1 having a DSC thermogram substantially as depicted in FIG.
2.
8. The solid form of claim 1 having a TGA thermogram substantially as depicted in FIG3.
9. A pharmaceutical composition comprising the solid form of any one of claims 1 to 8 and at least one pharmaceutically acceptable carrier.
10. A solid oral dosage form comprising the pharmaceutical composition according to claim 9.
11. Use of a solid form according to any one of claims 1 to 8 for the preparation of a medicament for inhibiting Pim kinases.
12. The use according to claim 11, wherein the Pim is Pim 1 kinase.
13. The use of claim 11, wherein the Pim is Pim 2 kinase.
14. The use according to claim 11, wherein the Pim is Pim 3 kinase.
15. Use of a solid form according to any one of claims 1 to 8 for the preparation of a medicament for treating cancer associated with Pim kinases.
16. The use according to claim 15, wherein the activity of Pim kinase is upregulated in the cancer, wherein the Pim kinase is at least one of Pim1, Pim2 and Pim3.
17. The method of claim 16, wherein the cancer is prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer, breast cancer, lung cancer, head or neck cancer, thyroid cancer, glioblastoma, sarcoma, bladder cancer, lymphoma, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma or multiple myeloma.
18. Use of a solid form according to any one of claims 1 to 8 for the preparation of a medicament for the treatment of a myeloproliferative disorder associated with Pim kinases.
19. Use of a solid form as claimed in any one of claims 1 to 8 for the preparation of a medicament for the treatment of an immune disorder associated with Pim kinases.
20. The use according to claim 19, wherein the immune disorder is an autoimmune disease.
21. Use of a solid form according to any one of claims 1 to 8 for the preparation of a medicament for the treatment of atherosclerosis associated with Pim kinases.
22. Use of the solid form of any one of claims 1 to 8 in the preparation of a medicament for reducing angiogenesis associated with Pim kinases or tumor metastasis associated with Pim kinases.
23. A method for preparing a solid form as described in any one of claims 1 to 8, comprising precipitating the solid form from a solution comprising N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide phosphate.
24. The method of claim 23, wherein the solution comprises a solvent comprising 2-propanol.
25. The method of claim 23, wherein the solution comprises a solvent comprising acetonitrile, ethanol, or both.
Citation Information
Patent Citations
Bicyclic aromatic carboxamide compounds useful as PIM kinase inhibitors
US20140200216A1
Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors
US20140200227A1
Furo- and thieno-pyridine carboxamide compounds useful as PIM kinase inhibitors
US20150057265A1
Wet milling process
WO2002000196A2
N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
WO2010135650A1
